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Abstract                                                            
 
Background: 
Approximately 1.7 billion people globally are infected with Mycobacterium 
tuberculosis (M.tb), the bacterium responsible for tuberculosis. The disease caused by 
this unassuming, microscopic pathogen has received the ominous title of the leading 
cause of death globally from a single infectious agent, ahead of both HIV/AIDS and 
malaria.  
 
Even though a diverse range of drugs are readily available to treat TB, their impact is 
barely felt in the face of the rapid development and spread of drug-resistant strains. 
Coupled with factors such as high disease burdens, low income settings, poor 
infrastructure and lack of treatment management and infection control measures, the 
impact of the shortage of effective drugs is further exacerbated by extended time to 
diagnosis, prolonged initiation of treatment, a lack of cheap, rapid diagnostic tools at 
the point of care and a shortage of effective drugs to treat drug resistant strains. A lack 
of treatment compliance results in resistance to old and newly discovered drugs, with 
extended TB treatment regimens necessitating the use of multiple toxic drugs. These 
therapies often present with severe side-effects and contra-indications, especially so in 
HIV-positive patients receiving ARVs. In most cases, this scenario results in eventual 
fatality.  
 
The development of an efficient and effective vaccine strategy to alleviate the impact 
and spread of TB is an appealing solution to ease the TB burden. An ideal vaccine 
against TB should aim to be as efficacious against drug sensitive strains, as they are 
against drug-resistant strains, irrespective of the resistance genotype. A successful 
approach toward TB vaccine development must accelerate efforts toward screening and 
discovery of suitable targets. 
 
The adhesin family of proteins is an attractive option to consider for such study and 
development. Within this arena, the two major M.tb adhesins, HBHA and MTP, offer 
a potential solution for vaccine development strategies. The 28-kDa heparin-binding 
haemagglutinin adhesin is the most predominant adhesin on the bacterial surface, 
facilitating dissemination of M.tb. The M.tb pili protein (unique to M.tb complex 
2 
 
organisms) aids in adherence to epithelial cells and stimulates the humoral immune 
response. These two candidates show promise for further study and development. 
 
A comprehensive understanding of the mechanisms of interaction of these proteins with 
the host can be garnered from combining molecular, biochemistry, cellular and 
microbiology techniques. The availability of phage-based gene knock-out methods 
allows for the mechanisms behind these interactions to be established, offering a novel 
method to assess the impact of functional gene expression on the phenotypic traits of 
an organism.  
 
This study aimed to elucidate the dual contribution of two M.tb adhesin proteins, 
HBHA and MTP, to growth, viability, biofilm production and the host–pathogen 
interactions in the KZN susceptible strain V9124. 
 
Materials & Methods: 
A novel dual-target gene knock out mutant (ΔhbhA-mtp) was generated in the 
F15/LAM4/KZN susceptible strain of M.tb, V9124. This phage-mediated process 
(mycobacterial specialized transduction) removed ~80% of the coding regions within 
the hbhA and mtp target genes, replacing them with selective screening markers. This 
resulted in non-functional HBHA and MTP proteins being expressed in a double mutant 
knock-out strain. The double mutant strain was used to construct independent ΔhbhA 
and -Δmtp complemented strains. These mutant and complemented strains were used 
to assess the effect of a combined loss of HBHA and MTP function on growth, viability, 
biofilm formation, adhesion and invasion capacity of pulmonary epithelial cells, in 
vitro. The F15/LAM4/KZN drug-sensitive strain served as the wildtype control. 
Growth variances were measured by colony forming unit counts and OD600nm readings, 
whilst viability was established by the resazurin microplate assay. Biofilm formation 
was assessed by means of crystal violet staining and quantification of cellular biomass. 
Adhesion and invasion assays were performed by infection of A549 pulmonary 
epithelial cells. 
 
Results & Discussion: 
The findings demonstrate the significance of these two major adhesins in facilitating 
growth and biomass formation. OD600nm measurements demonstrated significant 
differences among the strains across the 21-day period (p < 0.01). Optical density 
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measurements at OD600nm indicate a significant (p<0.05) difference in the growth of the 
double mutant relative to the growth of the wildtype strain. Growth was recovered by 
~50% when the double mutant was complemented to restore individual genes. Even 
though not significant, the removal of hbhA and mtp concurrently caused an 8.82% 
reduction in biomass relative to the wild type V9124, and suggest that MTP may have 
a greater effect on biofilm formation than HBHA. The viability assay indicated no 
significant (p>0.05) differences in the viability of the double mutant relative to the 
wildtype strain over the 21-day period, showing that these adhesins have no effect on 
the metabolic viability of M.tb. Both adhesins were also found to play a significant role 
in adhesion and invasion. The ability of the ΔhbhA-mtp double mutant strain (ΔDM) to 
adhere to A549 pulmonary epithelial cells was significantly reduced by 81% relative to 
the wild-type strain V9124 (p = 0.00). The invasive ability of the mutant was also 
reduced by 83% (p = 0.00). The outcomes allude to MTP performing a potentially 
greater role as an invasin than HBHA in the F15/LAM4/KZN susceptible strain V9124, 
whilst having similar roles as adhesins. 
 
Conclusions: 
The study was able to illustrate a potential compounded effect caused by a loss of 
function of two major adhesins on bacterial growth, and the vital pathogenic importance 
of the two major M.tb adhesins in promoting in vitro growth of the F15/LAM4/KZN 
susceptible strain. Their similar adhesin roles as presented in this study may allude to 
adhesion capacity being supplemented by upregulation and expression of additional 
primary and moonlighting adhesin molecules, as potential compensatory mechanisms 
implemented by M.tb in the absence of either one of the major adhesins.  
 
Over all, the outcomes indicate that HBHA and MTP may, in combination, present an 
attractive option as novel targets for potential vaccine/drug development, or as 
biomarkers for development within the point of care diagnostic device arena. Further 
studies looking into the impact of the absence of these genes on signalling pathways 
and gene regulation networks (both in M.tb and the host) would shed more light into 
the role they play in facilitating bacterial proliferation, and the potential effect that they 
may have on host immune modulation. They may also serve to indicate potential 
compensatory genes to be considered as additional novel therapeutic targets for 
development alongside hbhA and mtp. 
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CHAPTER 1: Introduction & Literature Review 
 
1. Introduction 
With one of the first documented descriptions being made by French military doctor 
Jean-Antoine Villemin in 1868, tuberculosis (TB) (derived from the word tubercle, 
meaning a small lump or nodule) is one of the oldest diseases known to affect mankind 
(Osoba, 2004; Shahverdi and Khani, 2017). A microbial disease caused by the acid-fast 
bacillus, Mycobacterium tuberculosis (M.tb), it is considered the most common fatal 
disease for adults worldwide (Shahverdi and Khani, 2017), and continues to cause more 
adult deaths than any other single infectious disease globally in the modern world 
(Gagneux, 2012). M.tb remains one of the most successful known human pathogens, 
having infected a quarter of the global human population by developing sophisticated 
and clever mechanisms to circumvent the host’s innate and adaptive immune defences.  
 
Exposure to M.tb and TB infection can be followed by several outcomes; rapid clearing 
of the bacilli  by activated innate immunity defence mechanisms, or immediate active 
disease (Coscolla and Gagneux, 2014). Most commonly, a latent infection may persist, 
and re-activate should the body become immuno-compromised, sometimes decades 
following the initial exposure (Coscolla and Gagneux, 2014). Approximately a third of 
the world’s population is regarded as latently infected with M.tb, and are at risk of 
developing active TB (Shahverdi and Khani, 2017). Active disease can be suspected if 
at least one of four suggestive symptoms is reported, including a prolonged fever, a 
persistent cough of two weeks or more, weight loss and night sweats (Sulis et al., 2016). 
 
Despite the ever-growing knowledge base available on pathogen transmission, 
diagnosis and treatment, this ancient disease continues to have a tremendous impact on 
public health, with much research remaining to be done in order to understand the 
complex intra- and extra-cellular dynamics of this globally debilitating infectious agent 
(Osoba, 2004; Fogel, 2015).  
 
Globally, the increasing number of new TB infections and fatalities each year is 
underpinned by a lack of effective diagnostic tests, drug-resistant strains, and a deadly 
relationship with the Human Immunodeficiency Virus/Acquired Immune Deficiency 
Syndrome (HIV/AIDS). Reducing the incidence of TB is a critical first step to eradicate 
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the epidemic (Fogel, 2015), but can only be facilitated by the development of improved 
diagnostics, and antimicrobial therapies and vaccines (Talbot and Raffa, 2015). This 
has sparked an intensified search for novel gene/protein targets for the development of 
therapeutic interventions to reduce the high TB infection burdens worldwide, as well 
as biomarkers to improve rapid diagnostics and patient outcomes (Zhang et al., 2006; 
Whitworth et al., 2013; Wallis and Peppard, 2015; Goletti et al., 2016). Currently, the 
microbiology and pathophysiology of TB are well studied and understood. This 
knowledge, combined with the application of rapidly evolving molecular techniques, 
and the power of genome sequencing tools have begun to unveil new insights toward 
infection control and prevention (Talbot and Raffa, 2015). Molecular biology 
experimental methods combined with in vivo animal studies have the potential to 
accelerate and support a deeper understanding of the complex biochemistry and cellular 
complexities of this robust and devastating infectious human pathogen. 
 
Understanding infection mechanisms (specifically how bacteria engage with the host 
cells), as well as identifying the key bacterial molecules that facilitate host adhesion 
and entry, is crucial in the search for novel biomarker and therapeutic drug targets 
(Govender et al., 2014; Ramsugit and Pillay, 2016; Squeglia et al., 2017). Combining 
knowledge of biochemical, cellular and molecular biology features of M.tb thus 
becomes fundamental in gaining an understanding of the pathogen, in order to design 
effective strategies with which to fight TB (Chang et al., 2007). 
 
Mycobacterium tuberculosis, like most pathogenic bacteria, requires a diverse range of 
molecules to survive and persist within the host (Lamichhane, 2011). These 
components are usually synthesized and presented by the host itself, or are obtained 
from the surrounding extracellular environment (Lamichhane, 2011). As a result of the 
significant impact that M.tb has had on global health, identifying key molecules central 
to persistence and longevity within the human host is appealing in the search for novel 
therapeutic targets (Glickman & Jacobs, 2001). In this arena, the generation and study 
of gene knockout mutants generated by molecular genetic approaches are extremely 
useful in that they allow for specific target M.tb genes and proteins to be studied in 
greater detail. This in turn facilitates understanding the genetic basis behind the roles 
that they may play in conferring virulence and persistence of the organism in the host 
(Bardarov et al., 2002).  
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Prior to 1996, the ability to carry out site-specific mutagenesis of M.tb was not possible, 
until allelic exchange mutagenesis with linear DNA substrates (in specific genes) was 
reported (Balasubramanian et al., 1996). The field rapidly took off, with intensified 
research giving rise to more efficient and less challenging methods with which to 
genetically manipulate M.tb, including stable mutagenesis techniques (transposon 
mutagenesis and site-directed mutagenesis) and allelic exchange methods (carried out 
using long and short linear DNA substrates, phagemid systems, counter-selectable 
markers such as sacB and a range of other recombineering systems) (Lamrabet and 
Drancourt, 2012).  
 
A high degree of genetic novelty within bacteriophages has positioned them to take 
center-stage in the advancement of bacterial genetic studies. Within the field of 
mycobacterial genetics, mutagenesis and allelic exchange can now be performed easily 
and efficiently using either mycobacterial extrachromosomal or plasmid vectors 
(Lamrabet and Drancourt, 2012). The modification of phages to encode recombineering 
systems based on mycobacteriophage Che9c proteins facilitating the development of 
new tools for manipulation of bacterial genomes (Marinelli et al., 2012) has 
revolutionized the construction of single-and multi-targeted gene-knockouts and point 
mutations in the slow-growing M.tb. 
 
The method of mycobacteriophage mediated specialized transduction effectively 
enables DNA transfer in mycobacteria, subverting a number of the challenges posed by 
the application of electroporation methods of genome manipulation, such as bacterial 
aggregation (clumping) and a high rate of illegitimate non-specific recombination 
(Aldovini et al., 1993; Kalpana et al., 1991; Bardarov et al., 2002). By utilizing a 
naturally-occurring infectious agent in the form of a mycobacterial virus, the general 
limitations to genetic exchanges (such as the thick, mycolic acid-rich cell wall and 
polysaccharide, protein and lipid “capsule” which both facilitate mycobacterial growth 
as a dense “pellicle” structure, preventing DNA from being taken up) can be 
circumvented (Lamrabet and Drancourt, 2012). The high frequency of successful 
specific allelic exchange establishes the phage-based methods of specialized 
transduction as a powerful genetic mechanism for engineering targeted marked and 
unmarked mutant mycobacterial species (Bardarov et al. 2002). 
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The primary step in TB pathogenesis is regarded as adhesion of the M.tb bacterium to 
the host cell surface. This process is mediated by microbial surface adhesin molecules, 
which facilitate the invasion of M.tb into cells and the subsequent evasion of the 
immune system (Ramsugit and Pillay, 2016). Typically surface-exposed, bacterial 
adhesins additionally serve to establish bacterial cell aggregation by enabling cell-to-
cell interaction, and eventual formation of dense microbial biofilm “communities” 
(Barnhart & Chapman, 2006; da Silva Neto et al., 2009). Several studies have 
demonstrated the importance of the two primary M.tb adhesins, the heparin binding 
haemagglutinin adhesin (HBHA) and the M.tb curli pili protein (MTP) independently 
in pathogenesis, suggesting that they may be extremely suitable biomarkers for further 
investigation  (Pethe et al., 2001; Alteri et al., 2007; Esposito et al., 2012; Ramsugit et 
al., 2013; Naidoo and Pillay, 2017).  This is due largely to their key roles in facilitating 
extra-pulmonary dissemination and stimulation of the humoral response, respectively.  
 
Almost all antibiotics currently used in the treatment of M.tb target bacterial processes 
involved in cell growth (Aldridge et al., 2012). Variability in growth patterns in 
mycobacterial populations create very high frequency population diversity (Aldridge et 
al., 2012). This heterogeneity in growth states in mycobacterial cells is thought to be 
the underlying cause of differential antibiotic susceptibility (Aldridge et al., 2012). The 
quantification of liquid M.tb cultures over time to establish growth kinetics is 
challenged by the bacteria’s propensity to form clumps (Lambrecht et al., 1988). The 
quantification of colony-forming units (CFU) in relation to a specific unit volume of 
culture over time is regarded as the most reliable and reproducible method to establish 
the concentration of viable microorganisms in liquid culture (Davey et al., 2004; 
Peñuelas-Urquides et al., 2013). This approach is unfortunately laborious, requiring 
extensive time periods to establish reliable growth metrics, more so in the case of slow-
growing organisms such as M.tb (Damato et al., 1983; von Groll et al., 2010; Peñuelas-
Urquides et al., 2013). The value of such experiments cannot be underrated, as they 
provide a mechanism with which to understand the impact of genes, growth conditions 
and energy sources on diversification and growth, enabling a better understanding of 
tuberculosis biochemistry, infection and eventually treatment (Aldridge et al., 2012). 
 
The ability of organisms to form biofilm structures is a contributing factor to microbial 
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persistence, allowing pathogenic bacterial populations to survive and flourish, even 
when exposed to extreme environmental pressures (Costerton et al. 1999). M.tb has 
been reported as being capable of forming drug-resistant bio-films in vitro (Ojha et al., 
2008; Ackart et al., 2014). This ability is considered to contribute significantly to its 
pathogenicity, as these biofilms serve to form a protective barrier against antibiotics 
that are normally active against planktonic bacilli (Esteban and Garcia-Coca, 2018). A 
hypothetical model for M.tb biofilm formation postulates that “dormant” bacilli are 
arranged around the periphery of lesions close to open airspaces; exposure to oxygen 
results in reactivation of these bacilli (Orme, 2014). The slower growth rates and lower 
metabolic activity prevalent in biofilm communities is thought to perpetuate a higher 
tolerance to therapeutic treatment (Solokhina et al., 2017). Thus, the discovery of drug 
targets and further development of treatments with potential to attenuate and impede 
biofilm formation would define a novel mechanism with prospects to considerably 
reduce anti-TB treatment durations (Ojha et al.,2008; Esteban and García-Coca, 2018).  
 
The complex genetics and biochemistry, coupled with obstacles in infection control has 
largely driven the success and survival of this complex organism, resulting in a global 
crisis. A wealth of information has been garnered from epidemiological and basic 
science studies.  The scope of the problem, the control measures currently being 
implemented and their efficacy (or lack thereof), as well as the development of 
therapeutic drugs and diagnostic tools to address the disease burden, has been well 
covered in literature to date. 
 
It is clearly understood that despite good first- and second-line therapeutics being 
readily available to treat drug-susceptible TB, factors such as latency, an ineffective 
vaccine, a lack of rapid point of care diagnostic tests, persistence and prolonged 
chemotherapy regimens exacerbate the situation. This has driven the urgent search for 
novel drugs with sterilizing ability to target the bacilli and inhibit disease progression, 
in an effort to shorten the duration of treatment and reduce the risk of relapse (Betts, et 
al., 2002; Krieger et al., 2012). New drug compounds face the necessity of needing to 
be equally potent in their ability to sterilize both sensitive and drug resistant strains 
(Ambady et al., 2012). Unfortunately, in the on-going search for candidate antigens, the 
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number of potential novel targets to be developed as anti-TB vaccine and 
therapies remains few and far between (Carabali-Isajar et al., 2018).  
In an attempt to bridge this gap and add to the current body of knowledge, this study 
aimed to establish the effect of inhibiting functionality of the two major adhesin 
proteins, HBHA and MTP. A novel double gene knockout mutant strain of M.tb was 
generated and confirmed, and used to establish the dual effect of these surface-
associated proteins on growth kinetics, viability, biofilm formation, as well as the 
adhesion and invasion capacity of M.tb when infecting pulmonary epithelial cells in 
vitro. 
 
1. Literature review - preface 
The review below provides an overview and background to the current infectious 
disease pandemic caused by M.tb. The mechanisms behind infection, the immune 
responses mounted by the human host as well as current perspectives in therapeutics 
and diagnostics will be highlighted. The review gives some attention to the primary 
initiators in infection, the adhesin molecules, and elaborates on the use of molecular 
techniques in the study of the host-pathogen interactions. 
 
2.1. Mycobacterium tuberculosis – the immortal microbe 
A disease of antiquity, M.tb, the bacillus responsible for TB, emerged as a human 
pathogen with roots postulated to originate in Africa, from where it was able to colonize 
the world through the Out-of-Africa migrations of modern Homo sapiens (Gagneux, 
2012). The tubercle bacillus is phenotypically characterised by its slow growth, 
conserved genetic homogeneity, complex cell envelope arrangement, intracellular 
pathogenesis and dormancy traits (Cole et al., 1998). The bacterial population resulting 
from its widespread global reach is very large. However, the classical members of 
the M.tb complex (MTBC) - M. tuberculosis, M. bovis, M. bovis BCG, M. africanum, 
M. canetti and M. microti - continue to have very limited genetic diversity 
(Frothingham et al., 1994; Richter et al. 2003; Supply et al., 2013). Systematic 
sequence analysis of multiple loci on independent isolates concluded that the genome 
of M.tb is either relatively evolutionarily young, or is uniquely and unusually inert 
(Cole et al., 1998). 
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2.1.1. General morphology 
Morphologically, bacilli typically appear under light microscopy as straight, sometimes 
slightly curved rods, approximately 3-5 µm in length and 0.2-0.6 µm wide (Velayati 
and Farnia, 2012). With a slow doubling time (18 – 24 h), the individual microbes tend 
to vary in size and shape (long rods or coccobacilli) based on the general growth 
conditions and age of the bacterial culture (Flynn et al., 2011; Velayati and Farnia, 
2012). 
 
2.1.2. Cell wall structure 
The uniquely characteristic thick, lipid-rich cell wall of M.tb (composed of long-chain 
fatty acids, peptidoglycan, proteins and glycolipids) (Fig. 1.) is one of the benchmark 
features that has contributed to the infectious success of this pathogen (Flynn et al., 
2011; Kumar et al., 2013), and is considered to confer an advantage in stressful 
conditions of osmotic shock or desiccation (Jarlier and Nikaido, 1990). The structurally 
complex, mycolic acid cell wall positions the cell as practically impermeable to the 
majority of conventional antimicrobial drugs, limiting the number of treatment agents 
against TB (Jarlier and Nikaido, 1990; Kumar et al., 2013).  
 
Fig. 1: The Mycobacterium tuberculosis cell wall structure: the acid-fast cell wall contains a 
variety of glycolipids, peptidoglycan and mycolic acids. A layer of polypeptides and mycolic 
acids (free lipids, glycolipids, and peptidoglycolipids) sits over arabinogalactan/mycolic acid 
layer. Other glycolipids present include lipoarabinomannan and phosphatidyinositol 
mannosides (PIM). Porins are also present to enable hydrophilic molecules to move through 
the outer membrane of the cell wall. Image sourced from: Kaiser, 2018. 
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2.1.3. Metabolic adaptation 
The success of the bacteria can further be attributed to an enhanced metabolic 
flexibility; the prototrophic tubercle bacillus is able to assemble all its components from 
basic sources of carbon and nitrogen, while being able to utilize pre-existing 
synthesized organic compounds as a primary source of energy (Edson, 1951; 
Ramakrishnan et al., 1972; Niederweis, 2008). This biochemistry is central in enabling 
the bacilli to effectively adapt to fluctuating environmental changes over the course of 
infection. Thus, the survival of M.tb is not dictated by nutritional quality and physical 
conditions (as with other infectious bacteria), as these resilient organisms are able to 
efficiently adapt to stressors such as hypoxia, temperature changes, nutrient 
deprivation, pH, and a host of other exogenous factors (Velayati and Farnia, 2012). 
 
2.1.4. Evasion strategies 
Virulent M.tb complex species have established clever strategies to evade or modulate 
the host immune response to their favour (Forrellad et al., 2013). Most impressive is 
the ability of the bacterium to circumvent the hostile intracellular environment of the 
alveolar macrophage upon being engulfed. M.tb inhibits phagosome-lysosome fusion 
to effectively evade the acidic elements inside the phagolysosome, by recruiting host 
proteins, such as Coronin1, a tryphtophan aspartate containing coat protein (TACO) 
(Jayachandran et al., 2007). TACO is retained at the phagosomal surface once recruited 
by M.tb., where it activates calcium–calcineurin signalling, further inhibiting lysosome 
fusion with mycobacterial phagosomes (Fig. 2.) (Jayachandran et al., 2007). Lysosomal 
hydrolases, reactive nitrogen and reactive oxygen species - which ordinarily destroy 
intracellular bacteria - are subsequently rendered useless (Forrellad et al., 2013). 
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Fig. 2: The influence of M. tuberculosis on phagosome and endosome maturation; once 
engulfed, M.tb finds itself in a phagosome, where maturation is arrested at an early stage. 
The early phagosome-harbouring mycobacteria retains TACO (tryphtophan aspartate 
containing coat) proteins, which serve to prevent further maturation. M.tb inhibits 
phagosomal acidification with a V–H+ ATPase, preventing fusion with the endosomal 
pathway. Image sourced from: Kaufmann, 2001. 
 
2.2. The global healthcare crisis: tuberculosis 
Previously considered as an inherited condition, TB (the notorious white plague, 
consumption or phthisis) was defined by Robert Koch in 1882 as one of the first 
infectious diseases caused by a bacterial pathogen, Mycobacterium tuberculosis 
(Orgeur & Brosch, 2018). TB is considered the ninth leading cause of death worldwide, 
and is the leading cause of mortality from a single infectious agent, ranking above 
HIV/AIDS (WHO Global Tuberculosis Report, 2017). During 2017, an estimated 10 
million people developed active TB, and 1.6 million succumbed to the disease (WHO 
Global Tuberculosis Report, 2018). Of those that fell victim to death, 0.3 million were 
HIV-positive (WHO Global Tuberculosis Report, 2018). The WHO further estimates 
that 2017 saw over 558 000 new cases reported with resistance to the most effective 
first-line drug, Rifampicin, of which, 82% were diagnosed as having MDR-TB (WHO 
Global Tuberculosis Report, 2018). The global incidence in countries with a high 
prevalence is highlighted in Fig. 3 (WHO Global Tuberculosis Report, 2018), drawing 
attention to countries such as India, China, Indonesia, the Philippines and South Africa. 
South Africa ranks seventh amongst the high burden countries for TB ((WHO Global 
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Tuberculosis Report, 2017). Even though over a century of research has been 
performed, this non-discriminant agent of infection continues to cause death, despite 
the ready availability of cheap, efficacious, and curative therapy (Bermudez et al., 2002; 
Algood et al., 2003; Almedia et al., 2008; Chang et al., 2007). 
  
 
Fig. 3: WHO presentation of the TB incidence estimate in 2017, for countries with at least 100 
000 incident cases. The data places emphasis on the burgeoning epidemic present in Asian 
countries with a dense population demographic, such as India, China and Indonesia. Image 
sourced from: WHO Global Tuberculosis Report, 2018. 
 
2.2.1. Drug resistance 
The emergence of drug-resistant TB in recent years has contributed to the problem at 
hand, and is further driven by ineffective or delayed drug-susceptibility testing (Alva 
et al., 2013). Drug resistance arises when bacteria replicate in the presence of 
therapeutic drug concentrations that are only partially suppressive, resulting in the 
formation of mutants able to outgrow wild-type strains (van den Boogaard et al., 2009). 
Drug resistance to the most efficacious first line TB drugs, isoniazid (INH) and rifampin 
(RFP), is defined as multi-drug resistant TB (MDR-TB), while the more likely fatal 
extensively drug-resistant TB (XDR-TB) is classified as MDR-TB with additional 
resistance to further second line drugs (any fluoroquinolone, and to at least one second-
line injectable drug including capreomycin, kanamycin or amikacin) (Shah et al., 2008; 
Caminero et al., 2010; Alva et al., 2013; Caminero and Scardigli, 2015; Sulis et al., 
2016). Fig. 4 implicates 3 major populations (India, China and the Russian Federation) 
to be the predominant contributors to the current global MDR-TB epidemic, as they 
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cumulatively account for almost half of the recorded global cases (WHO Global 
Tuberculosis Report, 2018). Unfortunately, the prevalence of these resistant and 
extensively drug resistant strains continues to rise (Carabali-Isajar et al., 2018), with 
2017 statistics attributing 8.5% of MDR-TB cases as being extensively drug-resistant 
TB (XDR-TB). The emergence of totally drug resistant TB (TDR-TB) strains, which 
present with in-vitro resistance genotypes/phenotypes to all first and second line drugs 
(including isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, 
ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, ciprofloxacin, 
capreomycin and kanamycin) served as a stark and swift  call for countries to mobilize 
resources to accelerate implementation of proper treatment and monitoring protocols, 
especially in patients diagnosed as multi drug-resistant (Udwadia, 2012).  
 
 
Fig. 4: The estimated incidence of MDR/RR-TB in 2017, for countries with at least 1000 
incident cases indicates 3 major populations as the most significant contributors to the rising 
prevalence of MDR-TB; India, Russia and China. Image sourced from: WHO Global 
Tuberculosis Report, 2018. 
 
2.2.2. The HIV pandemic 
The HIV epidemic has resulted in the prevalence of M.tb increasing worldwide, with 
2017 statistics indicating a mortality rate of almost 300 000 people dying of HIV-
associated TB (WHO Global Tuberculosis Report, 2018). Alongside these fatalities, a 
further 900 000 new TB cases were recorded amongst the global HIV-positive 
population, of which 72% were reported out of the African continent (WHO Global 
Tuberculosis Report, 2018) (Fig. 5). South Africa’s current global position is largely 
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driven by the ever-increasing rates of HIV co-infection coupled with a high incidence 
of multi- and extensively drug resistant strain outbreaks (Calligaro and Dheda, 2013; 
O’Donnell et al., 2013; Calligaro, et al., 2014). In 2015, the average TB/HIV co-
infection rate across South Africa was 56.7%, with patients presenting with the highest 
co-infection rates in Gauteng (68.4%), Mpumalanga (68.1%) and KwaZulu-Natal 
(63.6%) (Van Leeuw and Loveday, 2015). Lower rates of TB/HIV co-infection were 
detected in The Eastern Cape (45.2%), Northern Cape (41.1%), Western Cape (38.5%). 
Durban, KwaZulu-Natal is regarded as the epicentre of the country’s TB/HIV co-
infection and the epidemic is staggeringly widespread across the province, into the most 
far-reaching parts, with TB/HIV co-infection rates touted as being the highest in the 
country in the notorious uThukela district (71.2%) (Van Leeuw and Loveday, 2015). 
 
 Epidemiologic data indicate HIV-infected individuals are much more susceptible to 
the disease than their healthy counterparts (Goletti et al., 1996). The effect of co-
infection on mortality on South Africans in the province is highlighted by a hospital 
post mortem-study of young inpatients (18-45 years) that found 94% of patients to be 
HIV+ and 69% of them to have active TB or be on TB treatment at the time of death 
(Cohen et al., 2010). This synergistic relationship combined with outside factors such 
as poverty, under-nutrition, diabetes, drug use and smoking can be held responsible for 
the overwhelming resurgence of TB as a serious global public health epidemic, one that 
is further exacerbated by a significant increase in the prevalence of multi-drug resistant 
strains (Ambady et al., 2012; WHO Tuberculosis Report, 2017). The significant effects 
of TB/HIV co-infection can be seen in the impact being made medically, socially and 
economically (Skvortsov and Azhikina, 2012).  
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Fig. 5: Estimates of HIV prevalence in new and relapse TB cases – within 2017, 900 000 new 
cases of TB were reported within the global HIV-positive population, with 72% of these cases 
reported out of Africa. Image sourced from: WHO Global Tuberculosis Report, 2018. 
 
2.3. Engaging the host: mechanisms of infection and the immune response 
2.3.1. Mechanism of infection 
M.tb host infection occurs by inhalation of aerosolized droplets of proteinaceous 
pulmonary secretions carrying infectious, live bacteria (Bermudez & Goodman, 1996). 
Inhalation of a very low dose of bacilli (usually 1–5 tubercle bacilli) is thought to be 
sufficient for infection to occur (Balasubramanian et al., 1994). Once the bacteria 
become seeded within the respiratory tree, the droplet nuclei (ranging between 5 and 
10 µm) localize within the alveoli (Volk et al., 1986). 
 
Bacilli interact with both the epithelial cells lining the alveoli and the target host cells 
(alveolar macrophages) (Bermudez & Goodman, 1996). Emerging evidence indicates 
that the alveolar epithelium, and the abundant pulmonary epithelial cells (considered to 
be the initial barrier faced by M.tb upon its entry into the human host) serve as a 
potential reservoir for  the organism and play a key role during progression to active 
disease (Pessolani et al., 2003; Scordo et al, 2017). Macrophages and dendritic cells 
become direct targets for infection and activation (Kapoor et al., 2013). The well-
documented M.tb infection model designates the alveolar macrophage as the primary 
host cell, where bacilli survive by disrupting the phagocytic cells’ bactericidal 
mechanisms and replicating in an intracellular phagosomal compartment (Bermudez & 
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Goodman, 1996; Harriff et al., 2014). This process is depicted in Fig. 6a, and is 
followed by the host immunity attempting to contain the infection by means of 
granuloma formation, as illustrated by Nunes-Alves et al. (2014) (Fig. 6b). 
 
 
 
Fig.6: a. Model of TB infection indicating aerosolization of bacilli and infection of 
macrophages, eventually resulting in granuloma formation. Image sourced from: Shiloh, 2018. 
b. TB granuloma formation to control and contain infection – granulomas may calcify to 
eradicate infection or caseate to burst and release dormant bacilli resulting in reactivation. 
Image sourced from: Nunes-Alves et al., 2014. 
 
 
 
a. 
b. 
18 
 
1.3.2.  Role of macrophages 
Infection of the alveolar macrophage is considered the formative step resulting in 
bacterial dissemination, granuloma formation and initiation of TH1-type immunity 
(Flynn et al., 2011; Silva et al., 2012). Activated dendritic cells initiate an immune 
cascade, by presenting the processed antigens to CD4 T-cells (Dreher and Nicod, 2002). 
Activated lymphocytes and infected macrophages respond rapidly to inflammatory 
chemokine and cytokine signals, migrating to the site of infection to form organized 
granulomas in which M.tb remains contained, entering into a drug-resistant state of 
dormancy (Kapoor et al., 2013). The infection is normally contained in the lung by 
formation of granulomas, where activated macrophages and other immune cells 
aggregate at the site of infection to restrict mycobacterial dissemination from the lung 
and limit tissue damage (Saunders et al., 1999; Smith, 2003). In the granuloma 
structure, some bacteria remain essentially dormant and contained for decades without 
any presentation of active clinical disease (latent TB) (Silva et al., 2012; Kapoor et al, 
2013). However, in the event that the immune system becomes compromised, the 
caseous granuloma can become unstable and rupture, releasing contained dormant 
bacteria able to reactivate, replicate and spread into the lung and other tissues to cause 
active TB (Smith, 2003; Kim et al., 2010; Forrellad et al., 2013). The role of alveolar 
macrophages in TB pathogenesis has thus, been extensively studied and is well 
documented (Fenton et al., 1996; Keane et al., 1997; Keane et al., 2000; Bell and 
Noursadeghi, 2018; Esmail et al., 2018). 
 
2.3.3. The role of epithelial cells 
In contrast to macrophages, the interaction between M.tb and the lung epithelial cells 
has not been studied  as extensively, even-though alveolar Type II pneumocytes and 
airway epithelial cells (AEC) initiate early defense mechanisms upon exposure to M.tb 
(Hariff et al., 2014). Although the primary mechanism of TB infection is via 
macrophages, within alveoli epithelial cells are present in far larger numbers than 
macrophages (Crandall and Kim, 1991). Additionally, these cells are able to mount a 
defense against infection via production of molecules such as cytokines, chemokines 
and antimicrobial B-defensins, surfactants, NO and other molecules that are able to 
enhance the anti-microbial function of infected macrophages, or kill M.tb directly (Roy 
et al., 2004; Sharma et al., 2007; Lee at al., 2009). Given the large number of epithelial 
cells (28000 type I and 1400 type II) relative to the limited number of alveolar 
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macrophages (between 50 and 100) present within the alveolar space, invading bacilli 
have a greater chance of survival within epithelial cells than in the harsh environment 
presented by the presence of unarrested phagosomes within the macrophage cytoplasm 
(Bermudez & Goodman, 1996; Ashiru et al., 2010).  
 
Mycobacteria are able to effectively invade and replicate both in macrophages and in 
epithelial cells located in the alveolar spaces of the lung (Li et al., 2012). Lung epithelial 
cells present a potentially ideal environment for infecting bacilli to replicate away from 
the bactericidal mechanisms mounted by macrophages in relative safety (Castro-Garza 
et al., 2002). M.tb is versatile in that it is capable of adhering to, invading and replicating 
within these pneumocytes ex vivo (Bermudez and Goodman, 1996; Mehta et al., 1996). 
Additionally, epithelial cells present a niche within which the bacilli are provided direct 
access to the host lymphatic and vascular systems (effected by a disruption and 
destruction of the alveolar vascular endothelium), without the need for carrier 
macrophages (Castro-Garza et al., 2002; McDonough and Kress, 1995; Dobos et al., 
2000).  
 
2.3.4. Host immune responses 
Healthy individuals mount a complex and multi-factorial immune response to M.tb 
infection.  Studies of the immune responses in infected lungs are of key interest due to 
the localized interactions within the organ which serve as primary infection control 
measures (Algood et al., 2003). The initial M.tb-epithelial cell interaction may 
potentially facilitate the recruitment of macrophages to the site of infection by secretion 
of chemokines (Alteri, 2005). Infection of host macrophage cells by M.tb bacilli  leads 
to the initiation  of a cascade of defined inflammatory events, primarily regulated by 
the production the inflammatory molecules IFN-γ and IL-2 by activated T-cells 
(Cooper, 2009; Sasindran and Torrelles, 2011). This encourages the release of 
inflammatory cytokines, such as tumor necrosis factor-α(TNF), interleukin-(IL)-12, IL-
6, IL-10 and IL-23 along with a variety of chemokines including (C-C) motif ligand 2 
(CCL2), CCL4, CCL5, and (C-X-C) motif ligand 8 (CXCL8) from infected alveolar 
and tissue macrophages (Algood et al., 2003; Sasindran and Torrelles, 2011). 
 
The factors that enable M.tb bacilli to persist in the presence of a strong immune 
response and that allow most people to control the initial infection remain poorly 
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understood. Rough estimates predict that only 5–10% of persons infected with M.tb 
actually present with active disease, whilst the vast majority of those infected contain, 
but do not eliminate and clear the initial infection (Algood et al., 2003). These latently 
infected individuals do not present with clinical symptoms of disease and are not 
contagious.  However, infection may reactivate to active TB if their immunity becomes 
severely compromised, as in the case of HIV infection.  
 
2.4. Vaccines, diagnostics and therapeutics - current perspectives  
 
2.4.1. Vaccines 
The vaccine Bacille Calmette–Guérin (BCG) came into being almost 100 years ago, 
after Albert Calmette (1863–1933) and Camille Guérin (1872–1961) passaged 
Mycobacterium bovis over 230 times every 14 days, on potato slices soaked in ox gall 
(Kaufmann et al., 2017). This painstaking task, which began in 1906, was an attempt 
to generate an attenuated vaccine against M.tb. Even though they had preliminary 
evidence for the safety and the protective capacity of their vaccine candidate in 1913, 
they continued on until the 230th passage before using animal models to verify its 
efficacy and safety (Kaufmann et al., 2017). To date, BCG continues to be the only 
licensed vaccine against TB. The vaccine is able to confer protection against extra-
pulmonary infection in infants (including meningeal infection), but is ineffective in 
preventing pulmonary TB (Cernuschi et al., 2018). Additionally, it must be stressed 
that the efficacy of the BCG vaccine remains complicated by the fact that BCG is not 
derived from a single, pharmacologically well-defined vaccine but is comprised of a 
pool of different BCG daughter strains (Oettinger et al., 1999). These strains have 
acquired phenotypic and genotypic variations as a result of ongoing sub-culturing 
across different laboratories (Bottai and Brosch, 2016). In a study performed by Zhang 
et al. (2016), 13 different BCG strains were compared in phenotypic and genotypic 
analysis - distinct levels of virulence, potentially linked to strain-specific duplications 
and deletions within genomic regions, were recorded across the various strains. 
 
The absence of a comprehensive and effective vaccine against pulmonary TB continues 
to be a major roadblock in treatment of pulmonary TB (Russell et al., 2010). This 
remains largely due to the duration it takes to move candidates through each stage of 
the development pipeline before a vaccine may become available and approved for 
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human use. As highlighted in the Global Report on Tuberculosis Vaccines (2018), 
within the current TB clinical and pre-clinical pipeline, fourteen TB vaccine candidates 
are currently in clinical trials (Fig.7). Of these candidates, only one vaccine, the Chinese 
candidate, Vaccae™, has entered Phase 3 testing. Late Phase 2 testing is underway on 
three vaccines, while ten are in earlier stages of assessment. An additional seven 
potential vaccines are in pre-clinical trials, and twenty novel vaccine strategies in 
discovery and development. 
 
 
Fig. 7: The current clinical and pre-clinical TB vaccine pipeline compiled using data provided 
by TBVI, Aeras and TAG. Image sourced from: Global Report on Tuberculosis Vaccines 2018 
Executive Summary. 
 
2.4.2. TB diagnostics 
Sputum smear microscopy is still heavily relied upon by many high-burden countries, 
although diagnostic technology has advanced considerably, with only 57% of global 
TB cases of bacteriologically confirmed, and even less undergoing drug susceptibility 
testing (Cox & Nicol, 2018). Although more sensitive and specific diagnostics are 
available, such as Xpert MTB/RIF automated rapid molecular assay (Cepheid, USA), 
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the high cost factor in comparison to other commonly implemented laboratory methods 
has restricted implementation to high burden regions (Kelamane et al., 2015; Cox & 
Nicol, 2018). The abilities to detect TB early and provide effective and continuing care 
in such populations are essential to curtail further transmission (Dara & Zachariah, 
2018). 
 
 
Fig. 8: TB diagnostics pipeline showing recent and future POC devices. Image sourced from: 
Denkinger, 2017. 
 
Currently, a range of phenotypic, serological and genotypic methods are applied in the 
diagnosis of M.tb. These methods include the abovementioned GeneXpert MTB/RIF 
automated rapid molecular assay, the Determine TB-LAM assay, MTBDRplus and 
MTBDRsl line probe assays (Hain Life Science), the Qiagen QuantiFERON®-TB Gold 
test interferon gamma test, other nucleic acid amplification tests (NAATs), traditional 
liquid/plate culture and drug susceptibility testing methods (Fig. 8). These all have their 
own pitfalls and advantages and thus, largely fall short in delivering a tool that meets 
the criteria set by the WHO in defining a comprehensive point of care diagnostic, 
outlined in Table 1. (World Health Organization, 2014, García-Basteiro et al., 2018).  
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Table 1: High priority target product profiles in development of an ideal TB point of care 
(POC) diagnostic tool, as defined by the WHO (2014) – adapted from García-Basteiro et al., 
2018 
 
As much as the most sensitive method of detecting M.tb remains bacterial culture 
(Dinnes et al., 2007, World Health Organization, 2011; Ryu, 2015), the method is 
cumbersome and drawn out, as bacilli take between 2-6 weeks to grow on solid culture 
media for interpretation. This method often requires the use of antibiotic-containing 
media, and is prone to risk of contamination due to the prolonged incubations (Nema, 
2012). Even so, the BACTEC microbial growth indicator tube (MGIT) liquid culture 
system remains the fastest form of culture system, producing results within 14-17 days 
(Dinnes et al., 2007; Gomathi and Kumar, 2014) with a limit of detection ~10–100 
cfu/ml versus that of molecular methods, which must detect ≤10 genomic copies of 
Mycobacterium tuberculosis (MTB) DNA (Reed et al., 2017). 
 
The Determine TB-LAM assay (which diagnoses TB by detecting the presence of the 
M.tb antigen lipoarabinomannan (LAM) in urine) has a lower sensitivity when 
compared to the Cepheid GeneXpert molecular assay, even-though it is an attractive 
point-of-care option due to its rapid turnaround time to result, ease of use and low cost 
(Lawn et al., 2013). The QuantiFERON®-TB Gold test test, which quantifies interferon 
gamma production in response to both the Culture Filtrate Protein (CFP)-10 and the six 
kilodalton Early Secreted Antigenic Target (ESAT-6), although affordable, quick and 
easy to use, has the downfall of showing cross-reactivity to other Mycobacterial species 
(including M. marinum, M. sulzgai and M. kansassi) (Helmy et al., 2012). Within the 
domain of NAATs, the Hain Genotype® MTBDRplus strip test facilitates the detection 
✓ Able to detect both pulmonary and extrapulmonary tuberculosis (TB) 
✓ Can be effectively used in TB presumptive cases with children, adults, HIV-positive or HIV-negative  
✓ A range of easily accessible body samples can be applied in testing 
✓ Can be easily used by health care workers with minimal training 
✓ Peripheral or rural community health facilities can apply the method successfully  
✓ The method can be performed throughout a broad range of temperature and humidity 
✓ Results are available in less than 20 minutes 
✓ Little to no maintenance required 
✓ Affordable – cost equivalent or less than 4 US $ per test 
✓ High sensitivity - similar to that of GeneXpert MTB/RIF for both pulmonary and extrapulmonary TB 
(if intended for use as a triage test, outcomes must be 95% comparable to culture results) 
✓ High specificity - similar to that of GeneXpert MTB/RIF for both pulmonary and extrapulmonary TB 
(if intended for use as a triage test, outcomes must be 80% comparable to culture results) 
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of rpoB, inhA and katG mutations, detecting M.tb infection amongst the presence of 
other infecting agents, such as HIV, while defining infection with drug resistant strains 
(Hillemann et al., 2007; Barnard et al., 2008). Additionally, the Hain Genotype® 
MTBDRsl is a rapid DNA-based test that enables detection of specific mutations linked 
to resistance to fluoroquinolones and second-line injectable drugs (SLIDs) (Theron et 
al., 2016). 
 
Even though research and development in the field of point of care tools and novel 
targets for diagnosis have taken off in recent years, most of the currently available TB 
point-of-care diagnostic tools lack one or more of the desirable WHO Target Product 
Profiles criteria (as per Table 1) to allow implementation in a rolled-out strategy 
(García-Basteiro et al., 2018). Innovative technologies able to provide effective early 
detection at an affordable price for low-income and rural settings remain few and far 
between. However, the commercially-available POC tests that are available, offer value 
in trying to gauge a better understanding of infection and control, thereby paving the 
way for development of a more applicable and effective tool for implementation within 
high-burden settings (García-Basteiro et al., 2018).  
 
2.4.3. Anti-TB therapeutics 
As a standard first line regimen, four drugs are administered at therapeutic doses 
(including isoniazid, rifampicin, ethambutol and pyrazinamide) under ‘directly 
observed treatment short-course (DOTS), a process that is implemented to ensure 
treatment compliance by monitoring administration of anti-tuberculous therapy under 
regular supervision (Pollett et al., 2016). MDR-TB treatment necessitates the use of 
additional second-line drugs, that are more expensive, less effective and more toxic 
than first-line regimens (Center for Disease Control and Prevention, 2006). 
 
Drug treatment of MDR-TB as stipulated by the WHO guidelines, recommend the 
combined use of at least four different drugs. Typical regimens include pyrazinamide 
with numerous second-line drugs (Falzon et al., 2011; Park et al, 2015). The remaining 
three drugs must comprise: ethionamide, a later-generation fluoroquinolone or 
prothionamide; an injectable parenteral agent (kanamycin, amikacin, or capreomycin), 
and one of either cycloserine or p-aminosalicylic acid (PAS) (Falzon et al., 2011). On 
average, only 54% of patients presenting with MDR-TB are treated successfully, with 
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diagnosis often being delayed or undetected (Dara & Zachariah, 2018). Extensively 
drug-resistant TB (XDR-TB) has far worse treatment outcomes (40% on average, but 
as low as 19% when the disease is perpetuated by strains with resistance phenotypes 
indicative of TDR-TB) (Sulis et al., 2016). The lengthy treatment regimens (18–24 
months) and higher number of drugs used for treatment in comparison to drug 
susceptible TB treatment (often causing severe and adverse side-effects) are considered 
to be key factors leading to treatment failure (Dara & Zachariah, 2018, Yang et al., 
2017).  
 
One of the most common reasons behind the lack of success in the initial anti-TB 
regimen in high-burden, resource poor settings, has been the inability to deliver a 
complete treatment to a patient. The shortage of drugs to treat the more commonly 
prevelant MDR- and XDR-TB strains in these zones further exacerbates the issue 
(Mwinga, 2001). Following from a 50-year drought without a new TB drug being 
released, 2012 saw the approval of two new medicines, delamanid and bedaquiline (by 
the US Food and Drug Administration (FDA) and by the European Medicines Agency, 
respectively) (Zumla et al., 2014; Gandhi et al., 2018; Huerga et al., 2018). This 
followed from the successful treatment of MDR-TB patients in clinical trials using 
TMC207 (bedaquiline) and OPC-67683 (delamanid) (Diacon et al., 2009; Gler et al., 
2012; Gandhi et al., 2018). South Africa has recently become the first country in the 
world to provide bedaquiline as part of the country’s national care regimen for people 
living with multidrug-resistant tuberculosis (MDR-TB), aiming to reduce longer 
treatment programs that typically make use of injectable drugs. Similarily, treatment 
plans for XDR-TB are currently being addressed in a clinical trial evaluating a novel 
regimen of linezolid, bedaquiline and pretomanid (an experimental drug from the same 
class as delamanid) (Gandhi et al., 2018). The preliminary findings as reported by The 
Global Alliance for TB Drug Development highlight a treatment regimen of only 6–9 
months, a surprising contrast to the recommended 24-month course. The WHO has 
encouraged the use of both these new drugs by creating guidelines in support of the 9-
month shortened MDR-TB regimen (Falzon et al., 2017). 
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Fig. 9: The current TB drug pipeline, highlighting drug leads, those in early development and 
candidates currently in Phase1,2 and 3 trials. Image sourced from: Working Group for New TB 
Drugs, adapted by Pai, et al. (2016). 
 
The New Drugs Working Group of the Stop TB Partnership compiles a pipeline based 
on independent feedback from drug development entities, giving focus to drugs in 
discovery, pre-clinical development and clinical development (Fig. 9). Within the 
clinical development phase, a combination of ten novel and recycled compounds are 
under evaluation in phase II trials or as a component of anti-tuberculosis (TB) drug 
regimens (Working Group for New TB Drugs, 2018). The phase II and phase III trials 
generally aim to combine these compounds in regimens that are significantly shorter 
and easier to implement, targeting therapy at individuals with first-line drug resistant 
TB (Pai, et al., 2016). 
 
TB treatment regimes, if successfully implemented according to recommendations, 
should reduce transmission and thus the number of individuals presenting with active 
TB (Cox & Nicol, 2018). However, the slow decline in disease burden along with an 
inadequate response to the surge of drug-resistant TB suggests a profound failure of 
public health globally, implying that TB programs, while reducing deaths, are 
insufficient to overcome other drivers, such as poverty, famine, political instability, 
migration, the global HIV pandemic and drug/alcohol abuse (Cox & Nicol, 2018; Millet 
et al, 2013, Naidoo, et al., 2007). 
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2.5. Adhesins: potential drug and vaccine targets 
 
To survive and persist within the host, M.tb synthesises and recruits a diverse range of 
biomolecules (Lamichhane et al., 2011; von Both et al., 2018). These biomolecules are 
often obtained from the host extracellular/ cellular environment but may also be 
synthesized internally (e.g. ESAT6 and CFP10, which actively enable the bacilli to 
evade the phagolysosome) (Lamichhane et al., 2011; von Both et al., 2018). 
Considering the small genome sizes of bacteria in general, the ability of proteins to 
carry out multiple functions allows pathogenic organisms to effectively maximize their 
limited genetic information (Dumke et al., 2011).  Identifying and characterising these 
persistence-facilitating molecules and establishing how they engage with human host 
components is an attrative prospect, due largely to the impact made by this assiduous 
pathogen on global health (Glickman & Jacobs, 2001). 
 
To develop effective therapeutic measures targeting the initial interaction between host 
cells and the pathogen, the appropriate proteins involved need to be identified, 
characterized, classified and their roles established. As with many pathogenic micro-
organisms, adhesion of the infecting agent to the host surface is thought to be a crucial 
prerequisite in the pathogenic process of TB infection, allowing for host colonization 
to be established (Barbosa et al., 2006; Squeglia et al., 2017). Mycobacteria display 
multiple surface proteins with primary and secondary adhesin function that interact 
with receptors on host cells (Menozzi et al., 2006). Many reviews have recently 
discussed these protein molecules in great detail, highlighting the alternative primary 
roles that some have, while discussing the mechanisms of adhesion to the bacterial 
surface and how they interact with host cells (Kumar et al., 2013; Govender et al. 2014; 
Ramsugit and Pillay, 2016). This information positions adhesin proteins as valuable 
pharmaco-therapeutic targets, as most adhesins play important roles in the life-cycle of 
mycobacteria and are core virulence factors (Squeglia et al., 2017). 
 
2.5.1. Heparin binding hemagglutinin adhesin 
Previously, the only adhesin/invasin described definitively for M.tb was the heparin-
binding haemagglutinin adhesin (HBHA). This is a 28-kDa surface protein virulence 
factor that facilitates the dissemination of M.tb from the site of primary infection by 
facilitating engagement with epithelial cells (Menozzi et al., 2006; Esposito et al., 
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2011). Pethe et al. (2001) employed an HBHA-deficient strain to show a significant 
reduction in the adhesion to and invasion of A549 pneumocytes, when compared to the 
wild-type. This study resulted in HBHA being regarded as the principal M.tb adhesin 
prevalent in its interaction with epithelial cells (Pethe et al., 2001). hbhA mutant strains 
show a reduced ability to bind epithelial cells and disseminate from the lungs to other 
tissues (Menozzi et al., 2006; Esposito et al., 2011). The two central steps in TB 
pathogenesis, namely bacterial aggregation and cell adhesion, are facilitated by HBHA 
(Esposito et al., 2012), with its effect on aggregation in M.tb visible in studies by 
Menozzi et al. (1996) (Fig. 10). This adhesin has also been shown to provide strong 
protection against M.tb in in vivo mouse models and is touted as a vaccine candidate 
against TB with great potential (Hougardy et al., 2007). As a diagnostic antigen, HBHA 
is also a marker to distinguish latent from active TB in humans as the presence of 
HBHA induces higher levels of IFN-γ in latent infection (Hougardy et al., 2007). 
 
 
 
Fig. 10: HBHA-mediated aggregation of M.tb, effectively induced by incubating 108 
bacteria/ml with final concentrations of  HBHA proteins purified from H37Ra. Images (left to 
right) indicate incubations with 5, 1.25, 0.15 and 0 µg protein/ml (final concentration). Image 
sourced from Menozzi et al. (1996). 
2.5.2. M.tb curli pili 
Pili (threads) are one of the most commonly found forms of bacterial adhesins, and 
interact with glycoprotein and glycolipid receptors localized on host cells (Esko & 
Sharon, 2009). These hydrophobic adhesion molecules are used by bacterial pathogens 
to initiate infection of host cells (Finlay & Falkow, 1997), with the adhesin tip aiding 
in their structural, virulence-associated functions (Telford et al., 2006). M.tb 
tuberculosis pili proteins (MTP) are produced during pathogenic adherence to epithelial 
cells (Fig. 11) and play a key role in stimulating the host humoral immune response 
(Alteri et al., 2007).  
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Fig. 11: Transmission electron micrographs captured by Alteri et al. (2007) demonstrate clear 
production of pili by M.tb strains - A. H37Rv, B. avirulent H37Ra, C. clinical isolate CDC155, 
D. purified MTP. MTP pili fibres are indicated with black arrows. (Mag: 45,000x). Images 
sourced from Alteri et al. (2007). 
Their role as a key adherence factor was cemented by studies that highlighted their 
involvement in cellular aggregation resulting in biofilm formation (Ramsugit et al., 
2013), as well as in the adhesion to and invasion of THP-1 macrophages (Ramsugit & 
Pillay, 2015) and A549 pulmonary epithelial cells (Ramsugit et al., 2016). The mtp 
gene sequence was also confirmed to be unique to M.tb complex strains and highly 
conserved amongst clinical isolates, establishing it as a novel and fitting biomarker for 
development as a TB diagnostic test (Naidoo et al., 2014). Naidoo et al. (2018) further 
highlighted the diagnostic suitability of MTP in designing a POC TB test to screen large 
patient pools; screening of TB positive and TB/HIV co-infected serum/plasma samples 
using a synthetic MTP peptide confirmed MTP expression during both TB infection, 
and TB/HIV co-infection. 
Several studies have confirmed the presence of more than one single major adhesin in 
M.tb, which may account for the successful pathogenicity of this organism (Kumar et 
al., 2013; Esparza et al., 2015; Ramsugit et al., 2016). More recently, Govender et al. 
(2014) reviewed this class of proteins, highlighting the moonlighting capabilities of key 
proteins in the biochemical and glycolytic pathways to present themselves for 
secondary use as adhesin molecules. 
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2.6. Bridging the gap: Applying molecular techniques in studying host-pathogen 
interactions 
An understanding of the genetic basis of TB drug resistance, host immune evasion and 
bacterial phenotype is key in developing new diagnostic, treatment and preventive 
strategies (Grandjean et al., 2017). A critical challenge in drug development is the 
identification of targets central to the survival of M.tb that are either completely absent 
or significantly divergent, in the host organism (Bellinzoni & Riccardi, 2003). Rapid 
technological advancements in the molecular tools available for genetic and proteomic 
studies in recent years has allowed for a greater intensity of research to be undertaken. 
To date, the currently available anti-tubercular drugs that effectively challenge 
infections target only a limited number of essential functions in the cell (Sassetti et al., 
2003).  
 
Application of molecular tools such as quantitative real-time polymerase chain reaction 
(qRT-PCR), microarray and whole genome/transcriptome sequencing, in conjunction 
with in vitro growth conditions mimicking the fluctuating environment within 
macrophages or granulomas (i.e. oxygen deprivation, nutrient starvation and iron 
limitation) allows for novel genes to be identified for potential application in vaccine 
or drug development (Zvi et al., 2008).  
 
2.6.1. Transcriptional techniques 
The development of techniques such as qRT-PCR, microarray, hybridization and RNA 
sequencing have allowed for the transcriptional responses of both host and pathogen to 
be explored during the infection process. Transcriptional techniques such as these, 
allow the interactions between host and pathogen to be followed and characterized 
throughout the process of infection, identifying and categorizing pathogenic 
mechanisms used by M.tb to modulate and navigate the immune response (Waddell & 
Butcher, 2007). The transition of bacteria through variable stages of active 
multiplication, dormancy and resuscitation can be better understood by means of 
transcriptomic studies carried out directly on granulomas in lungs, within phagocytized 
bacteria located in activated macrophages or in in vivo animal infection models (Zvi et 
al., 2008). The understanding of mycobacterial interactions with the host and the 
subsequent bacilli response has been enhanced by RNASeq expression studies carried 
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out in conjunction with human patient samples, in vitro tissue culture models, models 
of M.tb infection using murine or human derived macrophages and animal models (e.g. 
murine model of disease) (Waddell & Butcher, 2007).  
 
Expression analyses have the power to elucidate how infecting bacilli respond to the 
host environment, giving a holistic understanding of the metabolic profile of infecting 
bacilli, within the different niches that mycobacteria occupy and how they can adapt 
(Waddell & Butcher, 2007). In vitro gene expression studies carried out under 
conditions which mimic dormancy and/or reactivation provide a vast reservoir of 
information, and could potentially guide the development of new treatment regimens 
focussed on targeting dormant cells to reduce later relapse. (Caño-Muñiz, et al., 2018; 
Zvi et al., 2008). Development of post-exposure vaccines primarily assesses gene 
products identified as participating in adaptation of M.tb to the intracellular habitat as 
the bacilli transition from replication to dormancy, or resuscitate from dormancy (Zvi 
et al., 2008). 
 
2.6.2. Genome sequencing 
The practice of genome sequencing of mycobacterial strains combined with data from 
whole-genome DNA microarray and proteomics have been a focus in previous years 
(Coppola and Ottenhoff, 2018; Walzl et al., 2018). The whole genome sequencing of 
the H37Rv strain of M.tb provided a wealth of data regarding the proteome of this 
infectious organism, and provided new insights into core biochemical and physiological 
processes facilitating the survival of the bacilli (Cole et al., 1998; Tekaia et al., 1999b). 
The availability of the whole genome sequence of M.tb has placed TB drug research in 
a favourably advantageous position by providing genetic and bioinformatic tools that 
may be used to further study the potential of prospective drug targets for success 
(Bellinzoni & Riccardi, 2003). This milestone in TB research has paved the way for the 
use of advanced bioinformatics procedures, both in genomics and transcriptomics 
research, and has allowed for structural and functional information of critically 
important survival components whose biological roles were unknown or obscured to 
come to light (Tekaia et al., 1999b). The genome analysis of M.tb defined the major 
importance of lipid metabolism to the survival of the organism, and exposed the 
existence of two novel protein families, PE and PPE, with unusual amino acid 
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sequences (Tekaia et al., 1999a). Genome-wide studies by Sassetti et al. (2003) have 
shown that the predominant genes required for optimal growth of M.tb include a range 
of enzymes predicted to have essential metabolic functions. In this way, bioinformatic 
analysis has allowed for novel drug targets against the M.tb infection to be identified. 
Gene sequencing analysis has also become a popular tool in detecting drug resistance 
due to the increased accuracy that it provides over other drug resistance detecting 
technologies (Walzl et al., 2018). Next-generation sequencing (NGS) and whole 
genome analysis could potentially become a reference standard in identification of drug 
resistance genotypes (Walzl et al., 2018). 
 
2.6.3. Molecular genetics and mutagenesis techniques 
The development of molecular diagnostic technology testing for resistance to anti-TB 
drugs also continues to move forward rapidly. Of utmost urgency is the discovery and 
development of biomarkers detecting the progression from latent infection to clinical 
active disease (Walzl et al., 2018). Sophisticated bio-informatic computational tools 
together with serological studies and protein/gene expression studies are being applied 
alongside systems biology approaches in the discovery and validation of such 
biomarkers (Walzl et al., 2018).  Such systems-level approaches enhance and 
complement standard classical molecular biology techniques to investigate pathogens 
leading to an in-depth understanding of their interactions with the human host (Banaei-
Esfahani et al., 2017). 
 
In evaluating the role played by proteins in persistence and virulence, knockout mutants 
generated by targeting genetic approaches allow for the extensive study of specific 
genes in both in vitro and in vivo model systems (Boël et al., 2005). This type of work 
is valuable in that specific attenuated or potentially non-pathogenic strains can be 
generated for use in the development of vaccines (Boël et al., 2005). The technique of 
qRT-PCR applied in mutant or essentiality studies effectively assesses specific M.tb 
gene regulation, with the expression patterns noted in tissue culture or in vitro models 
of infection allowing for the complex interactions between pathogen and human host 
to be elucidated (Waddell & Butcher, 2007). Gene expression data overlaid onto 
metabolic pathway analyses become increasingly informative in understanding 
organisms such as M.tb, by helping to define the physiological state of infecting 
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mycobacteria (Waddell & Butcher, 2007). A large amount of data can be gathered on 
the functional significance of target genes (in areas of importance such as mRNA 
degradation, protein expression, processing and regulation networks) using 
mutagenesis and knockout/down techniques (Waddell & Butcher, 2007). 
The application of molecular genetics in the study of M.tb became a true reality upon 
application of methods transforming genomic DNA, such as transposon mutagenesis, 
directed allelic exchange, electroporation and phage-mediated specialized transduction 
methods for DNA transfer.  Such methods enable the engineering of mutant strains by 
generating specific and defined mutations in M.tb (Braunstein et al., 2002). 
These methods, although steadily being enhanced by further development, are faced 
with many of the same issues as other classical and molecular techniques. Progress is 
impeded by the common core difficulties faced when working with M.tb, including 
slow growth, the need for special biosafety precautions, as well as a tendency to 
aggregate and clump during growth which hinders the isolation of individual clones 
(Braunstein et al., 2002). 
 
2.7. Significance of the study 
 
The worldwide WHO End TB Strategy by 2035 targets a 95% reduction in TB mortality 
and a 90% reduction in TB incidence (Taghizade et al., 2016).  In order for us to 
significantly move closer toward reaching the targets, the development of a dual-effect 
vaccine with prophylactic effects in uninfected adults needs to take precedence. Such a 
vaccine should be able to serve as an immunotherapeutic adjunct to drug therapy 
intended to reduce treatment duration in those with active TB by reducing bacterial 
loads. 
 
The above review establishes and confirms a critical urgency in the need for discovery 
and validation of potential novel gene and protein targets, such as the adhesins HBHA 
and MTP, for drug and vaccine development, in an effort to eradicate TB. Thus, this 
study focused on establishing the effect of the combined removal of the two main 
adhesin proteins, to understand their roles independently and cumulatively on growth, 
viability and biofilm formation. In addition, the adhesion and invasion capacity of these 
molecules on epithelial cells, in vitro was elucidated. 
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2.8. Research design 
 
2.8.1. Aim of study:  
To establish the contribution of the known M.tb adhesin molecules, HBHA and MTP, 
in the pathogenesis of M. tuberculosis, by assessing changes in the host-pathogen 
interaction relative to the absence or presence of both genes in a double-knockout 
mutant strain of V9124. 
 
2.8.2 Study objectives 
1. Generate and confirm a single knock-out mutant of hbhA in the F15/LAM4/KZN       
    susceptible strain V9124 by mycobacterial specialized transduction 
2. Generate and confirm double mutant of hbhA-mtp in a confirmed hbhA mutant strain   
    by mycobacterial specialized transduction 
3. Complement the double mutant strain with both genes in plasmids independently, to    
    confirm restoration of gene function 
4. Perform growth and viability assays on double hbhA-mtp mutant strains concurrently  
    with the wildtype and complemented strains (Optical Density A600, Colony Forming    
    Unit counts and Rezazurin Microplate Assay) 
5. Evaluate host-pathogen interactions by assessing adherence to and invasion of A549  
    cell lines by the wildtype, single mutant, double mutant and complemented strains 
2.8.3. Thesis overview 
 
This thesis is comprised of 5 chapters: 
 
• Chapter 1 – a general introduction and literature overview of M.tb and the 
current issues relating to the disease, with rationale for the focus on adhesins 
and their potential for use in drug and vaccine development. 
 
• Chapter 2: “Mycobacterium tuberculosis adhesins: potential biomarkers as 
anti-tuberculosis therapeutic and diagnostic targets” – a published literature 
review focusing on the various families of M. tuberculosis adhesin molecules 
with discussion regarding the current need for novel vaccine targets and drug 
candidates  
 
• Chapter 3: “Mycobacterium tuberculosis heparin binding haemagglutinin 
adhesin (HBHA) and curli pili (MTP) are essential for in vitro growth, but 
not viability and biofilm production.” - original research paper discussing the 
rationale for targeting multiple adhesins for potential vaccine development, and 
elaborates on the technical deletion of two adhesin genes by specialized 
transduction followed by data generated from phenotypic assays. 
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• Chapter 4: “The Mycobacterium tuberculosis HBHA and MTP proteins 
jointly support adhesion to and invasion of A549 pulmonary epithelial 
cells.”  - original research paper discussing data generated from phenotypic 
assays utilizing the double mutant and complemented strains  
 
• Chapter 5 - synthesis of the data chapters, demonstrating how they are inter-
related, ending with the final overall conclusions, potential outcomes and 
recommendations for future perspective. 
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The above chapter presented a general introductory overview of the core issues and 
presented a brief background of Mycobacterium tuberculosis and the current issues 
relating to the disease. The problem statement rationalized the need for the study and 
the study design, and outcomes were briefly discussed. 
 
The next chapter is a published literature review focusing on the various M. tuberculosis 
adhesin molecules with discussion centered around some of the well-characterized and 
novel, putative M. tuberculosis adhesins. Additionally, the current need for novel 
vaccine targets and drug candidates, as well as the lucrative prospect of the use of 
adhesins as potential therapeutic targets is elaborated on. 
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1.1. Abstract 
Adhesion to host cells is a precursor to host colonization and the evasion of the host 
immune response. Conversely, it triggers the induction of the immune response, a 
process vital to the host’s defence against infection. Adhesins are microbial cell surface 
molecules or structures that mediate the attachment of the microbe to host cells and, 
thus, the host-pathogen interaction. They also play a crucial role in bacterial 
aggregation and biofilm formation. In this review, we discuss the role of adhesins in 
the pathogenesis of the etiological agent of tuberculosis, Mycobacterium tuberculosis. 
We also provide insight into the structure and characteristics of some of the 
characterized and putative M. tuberculosis adhesins. Finally, we examine the potential 
of adhesins as targets for the development of TB control strategies. 
 
1.2. Introduction 
M. tuberculosis, the etiological agent of tuberculosis (TB), continues to pose a 
challenge to global public health. Despite more than a century of research, this non-
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discriminant pathogen continues to infect roughly a third of the world’s population 
(WHO, 2013). Whilst there has been a significant reduction in TB cases and deaths in 
the past two decades, approximately 8.6 million new cases and 1.3 million people 
succumbed to the disease in 2012, despite the availability of cheap, efficacious, and 
curative therapy for TB (WHO, 2013). The synergistic relationship between HIV and 
M. tuberculosis infection, and the significant increase in the prevalence of multi-, 
extensively-, and totally-drug resistant (MDR, XDR, and TDR) M. tuberculosis strains 
(Gillespie, 2002; Fauci et al., 2008; Jassal & Bishai, 2009; LoBue, 2009; Velayati et 
al., 2009; Almeida Da Silva & Palomino, 2011) are largely accountable for the dramatic 
resurgence of TB as a serious global public health epidemic. This is further complicated 
by the lack of an effective vaccine (Russell et al., 2010), prolonged chemotherapy 
regimens (Mitchison & Davies, 2012), and adverse TB/HIV drug interactions 
(Luetkemeyer et al., 2011).  Knowledge on the mechanisms utilized by M. tuberculosis 
to infect the host would offer novel perspective and define new targets to facilitate the 
design and development of drugs that are effective against both sensitive and resistant 
organisms (Ginsberg & Spigelman, 2007), efficacious vaccines (Bermudez et al., 
2002), as well as crucially needed rapid, accurate, and cheap point-of-care tests (Wallis 
et al., 2010). 
It is well established that adherence molecules (adhesins) play a fundamental role 
in the pathogen-host interaction (da Silva Neto et al., 2009; Espitia et al., 2012). 
Invasion of host cells by bacteria is a complex process involving both bacterial and host 
cell determinants (Bermudez & Goodman, 1996; Danelishvili et al., 2003). Pathogenic 
bacteria, such as M. tuberculosis, must initially adhere to and invade eukaryotic cells 
as a survival mechanism, enabling host colonization and the evasion of host immune 
defences (Niemann et al., 2004; Pizarro-Cerdá & Cossart, 2006; Kline et al., 2009). 
Adherence and invasion mechanisms have been well studied in pathogenic bacteria and 
fungi (Finlay & Cossart, 1997; Pizarro-Cerdá & Cossart, 2006; Singh et al., 2012a; 
Monack & Hultgren, 2013; Foster et al., 2014). These have illustrated that adhesins are 
the key players in the interactions that occur between the pathogen and the host, 
operating either as intercellular adhesion molecules (ICAM) or substrate adhesion 
molecules (SAM) (da Silva Neto et al., 2009). In this capacity, they are able to facilitate 
either cell-to-cell or cell-to-extracellular matrix (ECM) adherence and are usually 
surface-exposed (da Silva Neto et al., 2009). Adhesins also function in surface 
colonization and bacterial cell aggregation by facilitating cell-to-cell contact, leading 
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to the formation of microbial community structures or biofilms, a key contributor to 
microbial persistence (Barnhart & Chapman, 2006). Adhesins are, therefore, essential 
to microbial pathogenesis and are considered important biomarkers for diagnostics and 
therapeutics. 
In this review, we focus on the role played by adhesins in TB pathogenesis; we 
discuss some of the major M. tuberculosis adhesins; and examine their potential as 
targets for the development of anti-TB strategies. 
 
1.3. The host-pathogen interaction and adhesins  
The initial interaction of the bacilli with the host immune system has been reported to 
occur in the lungs with the alveolar macrophage, the host cell within which M. 
tuberculosis replicates (Algood et al., 2003; Smith, 2003). Under optimal conditions, 
these immune cells engulf the bacterium into a phagosome, leading to its destruction 
(Dubnau & Smith, 2003). However, M. tuberculosis has evolved mechanisms that 
allow it to thrive within the harsh environment, by delaying phagosome maturation 
(Armstrong & Hart, 1971; Russel, 2001; Nguyen & Pieters, 2005). If this fails, the 
bacteria are able to escape death by entering the cytosol (van der Wel et al., 2007). TB-
infected macrophages can travel to the hilar lymph nodes and bloodstream (Henderson 
et al., 1963; Harmsen et al., 1985) and this interaction is critical in the dissemination 
and systematic spread of the pathogen. 
Although the primary mechanism of infection is reported to be via macrophages, 
epithelial cells are present in far larger numbers than macrophages within alveoli 
(Crandall & Kim, 1991). The first cells that M. tuberculosis encounter in the lung are, 
therefore, most likely to be epithelial cells. M. tuberculosis is versatile in that it is 
capable of infecting and growing in these pneumocytes ex vivo (Bermudez & Goodman, 
1996; Mehta et al., 1996; Ashiru et al., 2010). The M. tuberculosis-epithelial cell 
interaction may potentially precede invasion of the macrophage and could also then 
facilitate the recruitment of macrophages to the site of infection by chemokine secretion 
(Alteri, 2005). Epithelial cells also present a niche within which the bacilli are afforded 
direct access to the host lymphatic and blood systems without the need for carrier 
macrophages. This is affected by the disruption and destruction of the alveolar vascular 
endothelium due to the cytotoxicity of M. tuberculosis to human pneumocytes 
(McDonough & Kress, 1995; Dobos et al., 2000; Castro-Garza et al., 2002).  
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Dendritic cells are better antigen presenters than macrophages and are key players 
in the early stages of TB infection (Tascon et al., 2000) and activate T cells with specific 
M. tuberculosis antigens (Bodnar et al., 2001; Gonzalez-Juarrero & Orme, 2001). 
Dendritic cells, however, do not support intracellular growth of M. tuberculosis but 
maintain the live bacteria in vacuoles (Tailleux et al., 2003). Since dendritic cells are 
migratory, they may potentially facilitate the dissemination of M. tuberculosis in this 
way (Lipscomb & Masten, 2002).  
Microbial adhesins are crucial to bacterial attachment to host cells (Fig. 1.1). The 
interaction of bacterial adhesins with host cell receptors is a key determinant of host 
specificity and tissue tropism (Klemm & Schembri, 2000). Furthermore, the cell surface 
location of adhesins and their role in attachment to host cells leads to the triggering of 
immune responses, which are crucial to the host’s defence against infection (Barnhart 
& Chapman, 2006; Bergsten et al., 2007).  
 
 
Fig. 1.1. The role of adhesins in the infection of host cells. Adhesins on the bacterium 
surface bind to molecules (ligands) on the host cell (in this instance, a macrophage) that 
are usually not meant for this purpose. This leads to invasion of the bacterium and its 
subsequent ability to survive and replicate within the host cell. 
 
1.4. Bacterial adhesins and their mechanisms of interaction with the host 
Adhesins serve to fulfil a common basic role, which is to initiate close contact with a 
receptor-like domain on the host cell surface, forming a fundamental link between the 
host and bacterium (Gerlach & Hensel, 2007). Infectious organisms have evolved to 
express novel adhesins that are able to bind to molecules ordinarily located on the 
eukaryotic cell surface. Molecules such as integrins, glycosaminoglycans, and specific 
sugar residues have all been shown to interact with adhesins of pathogens (Delogu & 
Brennan, 1999; Dersch & Isberg, 2000; Brennan et al., 2001). Most bacteria express a 
number of variable adhesins on their surfaces that have specific affinity to terminal 
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sugar residues or internal sequences in oligosaccharide chains that help to define the 
microbe’s ecological niche (Esko & Sharon, 2009). A range of adhesins have been 
described and characterized over the years. Lectin adhesins function predominantly to 
interact with glycan ligand receptors on the surface of host cells (Esko & Sharon, 2009). 
In addition, two major classes of protein adhesins have been defined to date: the 
fimbrial and the non-fimbrial adhesins (Gerlach & Hensel, 2007). Fimbriae (hairs) or 
pili (threads) are the most common form of bacterial adhesins. They are elongated, 
multi-subunit protein structures that are able to interact with glycoprotein and 
glycolipid receptors found on host cells (Esko & Sharon, 2009). 
In order to be functional, adhesins must be anchored onto or displayed on the 
bacterial cell surface with their functional domain on display (Chhatwal, 2002). 
Bacteria have developed several anchoring mechanisms involving the presence of a 
signal peptide or unique motifs (Chhatwal, 2002). The majority of adhesins function by 
binding ECM components, such as fibronectin. This is often considered to be an 
essential binding molecule facilitating bacterial adherence, due largely to its ability to 
bind both host cells and bacteria (Henderson et al., 2011). Fibronectin is also regarded 
as an effector in the triggering of signal transduction events that result in bacterial 
invasion of eukaryotic cells through interaction with integrins (Joh et al., 1999; 
Chhatwal, 2002). M. tuberculosis, specifically, has been shown to express adhesins that 
are capable of binding to ECM proteins, such as proteoglycans and fibronectin 
(Brennan et al., 2001). 
Proteins commonly secreted by bacterial pathogens can, in some instances, be 
‘anchorless adhesins’ which facilitate colonization of host organisms (Gerlach & 
Hensel, 2007).  Following their secretion, they accumulate and re-associate with the 
bacterial surface where they are able to execute biological functions, including host 
adherence and entry (Bergmann et al., 2001; Chhatwal, 2002).  
 
1.5. Adhesins central to M. tuberculosis pathogenesis 
Several studies have identified multiple M. tuberculosis proteins capable of interacting 
with receptors on host cells to facilitate binding to mammalian components and these 
are classified as mycobacterial adhesins (Fig. 1.2) (Menozzi et al., 2006; Kumar et al., 
2013). Pethe et al. (2002) identified a laminin binding protein involved in cyto-
adherence by its recognition of laminin. Kinhikar et al. (2006) showed that the 
glyoxalate pathway enzyme, malate synthase (glcB; Rv1837c), binds to the human 
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ECM proteins laminin and fibronectin and is an anchorless adhesin. The 19-kDa 
lipoprotein antigen (Rv3763) present on the cell wall preferentially binds to THP-1 
macrophage-like cells (Diaz-Silvestre et al., 2005). The cell surface glycoprotein Apa 
(Rv1860), initially considered a secreted molecule, has been shown to transiently 
associate with the cell wall in order to allow attachment to the pulmonary surfactant 
protein-A (PSP-A) (Ragas et al., 2007). The Cpn60.2 molecular chaperone protein 
(GroEL2; Rv0440), believed to be involved in bacterial pathogenicity and considered 
essential for cell viability, appears to be necessary to facilitate efficient bacterial 
association with macrophages (Stokes et al., 2004). Recently, Kumar et al. (2013) 
identified Rv2599 (membrane protein), Rv0309 (L,D-transpeptidase), and Rv3717 (N-
acetylmuramoyl-L-alanine amidase) as novel adhesins of M. tuberculosis H37Rv, 
capable of binding to laminin and fibronectin. 
 
 
Fig. 1.2. Selected M. tuberculosis adhesins and the multiple pathways available for 
initiating host interaction and colonization (Modified from: Kumar et al., 2013). 
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1.5.1. Heparin-binding hemagglutinin adhesin (hbhA; Rv0475) 
The most characterized and major adhesin in M. tuberculosis is the 28-kDa heparin-
binding hemagglutinin adhesin (HBHA). This surface-exposed protein is a virulence 
factor that facilitates the dissemination of M. tuberculosis from the site of primary 
infection by initiating interaction with host epithelial cells (Menozzi et al., 1996; 
Menozzi et al., 1998; Pethe et al., 2001; Menozzi et al., 2006; Esposito et al., 2011). 
The two crucial steps in TB pathogenesis, namely bacterial aggregation and cell 
adhesion, are facilitated by HBHA (Menozzi et al., 1998; Esposito et al., 2012). HBHA-
mediated aggregation is instrumental in the formation of bacterial clumps, allowing for 
more effective adherence and invasion (Esposito et al., 2012; Lebrun et al., 2012). A 
definitive role for HBHA in the facilitation of host adherence was shown by Menozzi 
et al. (1996) in which antibodies directed against HBHA inhibited attachment of 
mycobacteria to epithelial cells. In support of this, patients with active TB have been 
shown to produce anti-HBHA antibodies, suggesting HBHA expression during human 
infection (Menozzi et al., 1998). The carboxy-terminal lysine-rich domain of HBHA 
functions in recognizing heparan sulphate-containing receptors on epithelial cells 
(Delogu & Brennan, 1999; Pethe et al., 2000). Pethe et al. (2001) showed that 
colonization of a M. tuberculosis hbhA mutant strain in the lungs of mice was 
equivalent to that of the wild-type strain. However, the mutant displayed a reduced 
capacity to disseminate from the lungs to other regions of the body, suggesting the role 
of HBHA in extrapulmonary spread. The authors also showed that an antibody against 
the carboxyl-terminal domain of HBHA blocks binding to epithelial cell receptors, 
impeding extrapulmonary spread of M. tuberculosis in the mouse model (Pethe et al., 
2001). This suggests that the humoral immune response to HBHA, and possibly other 
M. tuberculosis adhesins, could potentially play a protective role in blocking 
dissemination from the lungs (Alteri, 2005). 
 
1.5.2. M. tuberculosis pili 
Pili proteins are hydrophobic adhesion molecules used by a wide range of bacterial 
pathogens to infect host cells (Finlay & Falkow, 1997). Structurally, pili are generally 
composed of pilin subunits with an adhesin tip, fashioned into straight or flexible 
filaments 1-10 nm wide and 0.07-3 µm long (Telford et al., 2006). Several virulence-
associated functions, including agglutination of human and animal erythrocytes, 
bacterial adherence/aggregation, biofilm formation, and adherence and colonization of 
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mucosal surfaces can be functionally attributed to pili (Strom & Lory, 1993; Finlay & 
Falkow, 1997). The hydrophobicity of the pilin adhesin enables interaction between 
bacteria and eukaryotic cells (Klemm & Schembri, 2000). Several distinct pilus types 
have been identified, the most characterized of which are the type I pili (produced by 
enteropathogenic Escherichia coli), type IV pili (produced by E. coli and Pseudomonas 
and Neisseria species), and curli pili (produced by some strains of E. coli) (Telford et 
al., 2006). The previous misconception that mycobacteria are not piliated was clarified 
by Alteri (2005), who proved, using transmission electron microscopy of negatively-
stained bacilli, that M. tuberculosis produces two physically-distinct pili morphotypes: 
type IV and curli-like pili (MTP). 
The type IVB pilus locus of M. tuberculosis encodes a prepilin of the Flp pili family 
(Alteri, 2005). In addition, the proteins encoded by the Rv0990c and Rv2551c ORFs 
are thought to be involved in the secretion or cleavage of the Flp prepilin substrate 
(Alteri, 2005). Genetic analysis revealed that M. tuberculosis acquired these genes by 
horizontal gene transfer as the flp genes were shown to be flanked by multiple direct 
repeats, suggesting insertion of foreign DNA into its chromosome (Alteri, 2005). The 
role of this pilus type as an adhesin in this organism has yet to be determined. In Gram-
negative organisms, type IV pili function in adherence to host tissue, co-aggregation, 
immunomodulation, motility, and DNA uptake (Telford et al., 2006). 
Alteri et al. (2007) showed that purified MTP are comprised of 4-kDa protein 
subunits, encoded by the Rv3312A ORF. These researchers also demonstrated that 
MTP are produced during pathogenesis and play a role in stimulating the humoral 
immune response. This was evidenced by the sera of patients with active TB containing 
IgG antibodies against MTP (Alteri et al., 2007). Furthermore, MTP binds to laminin 
in vitro and are produced during adherence to epithelial cells, implying that they serve 
as an adherence factor that is crucial in mediating close interaction and colonization 
with host cells (Alteri et al., 2007). Their role as an adherence factor was further 
substantiated by their involvement in cellular aggregation and biofilm formation 
(Ramsugit et al., 2013) and in the adhesion to and invasion of THP-1 macrophages 
(Ramsugit & Pillay, 2014). 
 
1.5.3. Apa (alanine-proline-rich antigen; Rv1860) 
The 45-47-kDa secretory and cell surface antigen Apa (alanine-proline-rich antigen; 
Rv1860) is a mycobacterial glycoprotein whose expression appears to be restricted to 
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the members of the M. tuberculosis complex, including the vaccine strain M. bovis 
Bacille Calmette-Guérin (BCG) (Ragas et al., 2007; Nandakumar et al., 2013). The 
secreted antigen is not present in other mycobacterial species, including M. avium, M. 
marinum, or M. smegmatis (Ragas et al., 2007; Nandakumar et al., 2013). Apa is 
targeted by, and binds directly to the human PSP-A, an innate immune system C-type 
lectin responsible for early recognition of invading pathogens (Ragas et al., 2007). The 
secreted antigen remains associated with the cell wall only long enough to facilitate its 
attachment to PSP-A. Ragas et al. (2007) demonstrated the presence of a structural 
determinant in the manno-oligosaccharide moiety that has been highly implicated in 
the adhesion function of the protein. They also confirmed the adhesion function of Apa 
during TB infection and pathogenesis. The immune-dominant Apa possesses 
fibronectin-binding activity and is strongly recognized by serum antibodies of active 
TB patients. In addition, it shares significant amino acid homology with a fibronectin 
attachment protein family common to other mycobacterial species, including M. avium, 
M. marinum, and M. leprae (Nandakumar et al., 2013). In M. tuberculosis specifically, 
mannosylated Apa plays a key role in host cell interaction (Nandakumar et al., 2013). 
Apa has been proposed as a possible vaccine candidate or component for future 
vaccines against TB. This has been supported by Nandakumar et al. (2013) who showed 
Apa to offer significant protection against virulent M. tuberculosis in mice when used 
as a BCG-booster vaccine. 
 
1.5.4. Malate synthase (glcB; Rv1837c) 
The glyoxalate shunt, a key pathway in fatty acid metabolism of M. tuberculosis during 
persistent infection, has long been hypothesized to be a weakness in the bacteria’s 
armour that could potentially be exploited for the development of anti-tubercular 
therapeutics (Krieger et al., 2012). Da Silva Neto et al. (2009) showed that malate 
synthase, an enzyme of the glyoxalate pathway, from Paracoccidioides brasiliensis is 
a multifunctional protein, with a dual role as an enzyme and mediates adherence of the 
fungus to host cells via its ability to bind fibronectin and type I/type IV collagen. Malate 
synthase has been suggested to be actively secreted by this fungal pathogen in a similar 
manner to M. tuberculosis (da Silva Neto et al., 2009). In M. tuberculosis, the single 
malate synthase encoded by glcB is thought to play a key role in pathogenesis by 
imparting some degree of virulence to the bacteria (Dunn et al., 2009). Kinhikar et al. 
(2006) have demonstrated in vivo expression of malate synthase to be typical during 
60 
 
active infection, with the enzymatic function suggesting a general cytoplasmic 
localization of the protein. However, this protein was also consistently identified as a 
secreted protein in the growth medium filtrates of mid-log phase cultures (Kinhikar et 
al., 2006). Studies have shown that secreted malate synthase enhances the adherence of 
the pathogen to lung epithelial cells by binding to the glycoproteins, laminin and 
fibronectin (Kinhikar et al., 2006; Dunn et al., 2009). The binding activity of malate 
synthase was shown to be mediated by the presence of a unique C-terminal domain. 
These features, together with the marked absence of a conventional secretion 
mechanism or defined cell wall anchoring motif, resulted in the malate synthase of M. 
tuberculosis being classified as an anchorless adhesin that is able to contribute to 
bacterial virulence by facilitating infection of the host and dissemination (Kinhikar et 
al., 2006).  
 
1.5.5. Glyceraldehyde-3-phosphate dehydrogenase (gap; Rv1436) 
The GAPDH protein family is known to have diverse functional activity depending on 
the sub-cellular location, secondary to its primary role in glycolysis and central carbon 
metabolism (Barbosa et al., 2006). Several authors have indicated that GAPDH may be 
either secreted or expressed on the cell surface in both Gram-positive and Gram-
negative bacteria, parasites, and fungi (Pancholi, 2001; Pancholi & Chhatwal, 2003; 
Matta et al., 2010; Jin et al., 2011). In support of this, the GAPDH of group A 
streptococci has been shown to be membrane-bound and is able to bind fibronectin, 
lysozyme, and myosin and actin cytoskeletal proteins, pointing toward an additional 
function leading to bacterial colonization (Barbosa et al., 2006). The unusual 
extracellular localization of GAPDH has been confirmed in a broad range of other 
microorganisms, including Staphylococcus spp., Neisseria meningitidis, E. coli, P. 
brasiliensis, Trichomonas vaginalis, and Candida albicans (Dumke et al., 2011). 
The surface-localized equivalent proteins have also been shown to remain 
enzymatically active and are transcribed from the same ORF as the cytoplasmic 
molecules (Purves et al., 2010). In its role as a surface-associated protein, GAPDH is 
able to interact with both specified host factors like fibronectin, fibrinogen, albumin, 
laminin, collagen, and plasminogen, as well as human epithelial and endothelial cells 
and fimbriae of other bacterial species (Dumke et al., 2011). GAPDH, specifically, has 
been shown to be important in the pathogenesis of Staphylococcus aureus infections 
(Purves et al., 2010). Tunio et al. (2010) showed a N. meningitidis gapA mutant to 
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adhere significantly less to human cells when compared to wild-type strains. 
Additionally, Boël et al. (2005) indicated that inhibiting export of GAPDH to the 
surface of group A streptococci affected its virulence by reducing adherence to target 
cells. 
Despite the existence of a large body of literature on bacterial cell surface GAPDH, 
only two studies have shown direct evidence for the role of GAPDH as a cell surface 
protein that plays a role in bacterial virulence (Henderson & Martin, 2011). This is most 
likely attributed to the essentiality of the gene in its primary function in glycolysis, 
resulting in the inability to inactivate the encoding gene (Henderson & Martin, 2011). 
It is, thus, not surprising that a cell surface GAPDH knockout has, to date, not been 
evaluated in vivo. 
 
1.5.6. Chaperonins as adhesins (dnaK and groEL2; Rv0350 and Rv0440) 
Although a number of heat shock protein classes have been identified, GroESL and 
DnaK are regarded as the major response systems within bacteria (Singh et al., 2012b). 
The molecular chaperones constitute a diverse set of conserved proteins in bacteria, 
encoded by the essential heat shock protein genes groEL and groES. These genes, also 
called cpn60 and cpn10, mediate the correct assembly, folding, transport, and 
degradation of other proteins in vivo (Qamra et al., 2004; Shahar et al., 2011; Singh et 
al., 2012b). M. tuberculosis contains two copies of the cpn60 genes, with one of these 
genes, cpn60.1, organized in an operon with cpn10, while the second, cpn60.2, is 
arranged separately in the genome and is expressed from the myc28 gene (Qamra et al., 
2004; Lewthwaite et al., 2007; Shahar et al., 2011).  
Recent mycobacterial studies demonstrated the unusual presence of the Cpn60s on 
the outside surface (capsule) of the bacterial cell. This is despite the predominant role 
of these proteins in the cytoplasm and the lack of a secretion signal sequence or other 
known motif implicating its export (Qamra et al., 2004; Shahar et al., 2011; Zhu et al., 
2013). Hickey et al. (2009) have shown both the molecular chaperones Cpn60.2 and 
DnaK to be surface components of the mycobacterial capsule in cultured bacilli. The 
authors also showed Cpn60.2 to bind to the surface of macrophages at sites required for 
efficient association with M. tuberculosis bacilli, and that blocking surface-localized 
Cpn60.2 with antibodies resulted in a reduction of bacterial binding. Additionally, 
Hickey et al. (2009) showed that the Cpn60.2 protein is a major mycobacterial adhesin, 
which is able to stabilize the interaction between the pathogen and the alveolar 
62 
 
macrophage through CD43. Such studies implicate Cpn60.2 as having a secondary 
function as an adhesin molecule (Hickey et al., 2010; Shahar et al., 2011). They 
provided further evidence that mycobacterial molecular chaperone/cell stress 
molecules are vital moonlighting proteins, which are able to promote bacterial survival 
and virulence due to their irregular position outside of the cell (Henderson et al., 2010).  
It was hypothesized that the secondary, extracellular functionality of these 
molecular chaperones may allow for synergism with the intracellular cell stress 
response in order to generate a novel homeostatic network of interactions (Henderson 
et al., 2010). Although the Cpn60.2 protein is expressed from outside the GroEL/ES-
like operon, studies have shown the protein to be essential for survival, with deletion 
of the genes encoding Cpn60.2 completely preventing the growth of M. tuberculosis 
(Shahar et al., 2011). Hu et al. (2008) demonstrated an inability to produce M. 
tuberculosis mutants lacking the cpn60.2 gene through recombineering, further 
suggesting the essentiality of this gene. Hickey et al. (2009) have shown that although 
both Cpn60.2 and DnaK proteins are present on the bacterial surface, only the former 
seems to be required to facilitate efficient bacterial interactions with macrophages. 
 
1.6. Adhesins as targets for the development of TB control strategies 
Significant further research into identifying and characterizing M. tuberculosis 
adhesins is required in order to elucidate their precise role in virulence, establish the 
mechanisms behind their secretion, and to identify the receptors required for their 
association with the host cell surface. Uncovering the mechanisms of binding of 
adhesins to host cells will, therefore, lead to an improved understanding of the initial 
events that occur during TB infection. Such studies could potentially result in the 
development of novel strategies for infection control by means of therapeutics that are 
able to block secretion and/or prevent re-association with the cell membrane. Secreted 
proteins also have potential as biomarkers for diagnostic use, as such molecules are 
recognized with sensitivity during the humoral response to infection by M. tuberculosis. 
 
1.6.1. Development of anti-adhesives 
Greater understanding of the adhesin-ligand interaction may facilitate the design of 
competitive inhibitors that block their formation, as has been shown in several other 
organisms, including E. coli. The conjugation of the QFGGN amyloid motif from the 
E. coli CsgA curlin to proline residues was shown to inhibit bacterial curli formation 
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(Cherny et al., 2005). Bicyclic 2-pyridones, or pilicides, target the chaperone-usher 
interaction, blocking pilus biogenesis, and led to an inhibition of adhesion to bladder 
cells and biofilm formation in E. coli (Pinkner et al., 2006). A multivalent galabiose 
derivative is an inhibitor of adherence by E. coli P-fimbriae (Salminen et al., 2007). 
Similarly, α-D-mannose based inhibitors targeting the FimH adhesin prevent E. coli 
adhesion on uro-epithelial cells, invasion, and biofilm formation (Wellens et al., 2008).  
 
1.6.2. Adhesins as vaccine candidates 
The importance of adhesins in pathogenesis implies that disrupting bacterial attachment 
by specific anti-adhesin antibodies has the potential to incapacitate a pathogen (Klemm 
& Schembri, 2000). However, the large number of different adhesin genes in an 
organism’s genome suggests that there are multiple pathways for bacterial adherence 
(Brzuszkiewicz et al., 2006). This redundancy limits the use of adhesins as vaccine 
candidates (Kline et al., 2009). In addition, different adhesins are not produced 
simultaneously and continuously and require different environmental cues for 
expression and many exist as antigenic variants (Klemm & Schembri, 2000).  
Even with these constraints, adhesins in several species have proven to be useful 
vaccine candidates, capable of conferring protection in animal models. Their 
extracellular location is also a favourable feature in that it enables their interaction with 
protective antibodies (Telford et al., 2006). Their multiple functions in pathogenesis 
and modulation of the host immune response, together with independent signalling 
events mediated by individual components of polymeric adhesins, also produces a more 
robust immune response (Mandlik et al., 2008).  
A review by Kline et al. (2009) highlighted adhesive proteins as protective antigens. 
These include (amongst others): an E. coli FimH adhesin-based vaccine against cystitis 
in a primate model (Langermann et al., 2000), the E. coli Dr fimbrial antigen against 
urinary tract infection in mice (Goluszko et al., 2005), the Salmonella atypical fimbriae 
B chaperone (SafB) complexed with the SafD adhesin against invasive Salmonella 
enteritidis infection (Strindelius et al., 2004), a synthetic-peptide consensus-sequence 
vaccine (Cs1) against type IV pilus of Pseudomonas aeruginosa in a mice model (Kao 
et al., 2007), and a combination of three group B Streptococcus (GBS) pilus variants 
that mediate protection in mice against all tested GBS challenge strains (Margarit et al., 
2009). 
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1.6.3. Adhesins as serodiagnostic markers for M. tuberculosis 
Exposure to M. tuberculosis antigens leads to the production of specific antibodies, 
which may be used as markers of infection in serological tests. Several M. tuberculosis 
antigenic proteins have been evaluated as serological markers, particularly culture 
filtrate proteins, however, surface-exposed proteins appear to be more effective (Abebe 
et al., 2007).  
The 19-kDa lipoprotein adhesin is recognized by sera from TB patients and the 
sensitivity of this immuno-dominant antigen was found to be 62% in sputum smear-
negative TB patients (Jackett et al., 1988; Bothamley et al., 1992a, b; Greenaway et al., 
2005). The anchorless adhesin malate synthase is a surrogate marker for TB infection 
in HIV-seropositive individuals (Abebe et al., 2007), with 57% of TB-infected and 92% 
of TB-HIV co-infected patients in Uganda and South Africa, respectively, showing 
reactivity to this antigen (Hendrickson et al., 2000). The 30-kDa antigen (antigen 85B 
or α-antigen) binds to fibronectin and is regarded as a potential M. tuberculosis adhesin 
(Ratliff et al., 1988). The sensitivity of this antigen, however, was shown to have a 
broad range of variability, from 41-94% (Vikerfors et al., 1993; Lim et al., 1999; Raja 
et al., 2002; Uma Devi et al., 2003; Raja et al., 2004). Delogu & Brennan (2001) showed 
that mice infected with M. tuberculosis by aerosolization generated antibodies against 
the PE_PGRS protein Rv1818. This protein has been suggested to be an adhesin that is 
involved in both the infection of macrophages and in cell aggregation (Brennan et al., 
2001). 
HBHA may also be a useful target in TB diagnostics due to its presence in the early 
stages of TB infection (Masungi et al., 2002). Zanetti et al. (2005) reported that 80% of 
TB patients (n = 5) presented with increasing HBHA antibody titres over a four-month 
period. Two of these patients showed a high HBHA antibody level, even though they 
were tuberculin skin test negative. With regard to the onset of the immune response, 
methylation of HBHA appears to be crucial for the induction of T cell antigenicity and 
protective immunity against M. tuberculosis (Temmerman et al., 2004). Methylated 
HBHA may, thus, be a suitable diagnostic marker for identifying individuals with active 
TB (Abebe et al., 2007). 
It was recently shown that the mtp gene, encoding curli-like pili (MTP), is a 
conserved gene present in M. tuberculosis complex strains, but not in non-tuberculous 
mycobacteria or other respiratory bacteria (Naidoo et al., 2014). In addition, sera of 
patients with active TB are known to contain IgG antibodies against MTP (Alteri et al., 
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2007). MTP may, therefore, be a suitable marker for the development of a point-of-care 
TB test. 
 
1.7. Conclusions 
The involvement of M. tuberculosis surface molecules in adherence is essential to the 
increased understanding of the bacterium’s pathogenesis. However, little progress has 
been made in identifying and characterizing the contribution made by the specific 
adhesins utilized by this pathogen during infection of host cells. This can be attributed 
to a plethora of factors that include technical difficulties in generating gene knock outs, 
an inability to knock out genes of essential function, a lack of studies on M. tuberculosis 
entry into non-phagocytic cells, the previous mistaken notion that M. tuberculosis is 
non-fimbriated, and the under-appreciation of the pellicle biofilm lifestyle of this 
pathogen. Further work on identifying novel adhesins and defining their contribution 
to TB pathogenesis is critical to increasing our understanding of the physiology and 
molecular mechanisms of TB pathogenesis that may subsequently facilitate the 
development of new strategies for TB control. 
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The above paper presented a detailed a review that discussed the key function and importance 
of adhesins in the pathogenesis of the aetiological agent of tuberculosis, Mycobacterium 
tuberculosis. The review provides details regarding the features of both well-characterized and 
putative novel M.tb adhesins. The review provides rationale and advocates for the potential of 
adhesins as targets for the development of therapeutic strategies. 
 
In proof of this concept, the next chapter assesses the potential importance of HBHA and MTP 
as a combined target for therapeutic drug and vaccine development by establishing the in vitro 
growth, viability and biofilm formation capacity. 
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CHAPTER 3: Paper 2 – “Mycobacterium tuberculosis heparin binding 
haemagglutinin adhesin (HBHA) and curli pili (MTP) are essential for 
in vitro growth, but not viability and biofilm production.” 
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Abbreviations: hbhA/HBHA (heparin binding haemagglutinin adhesin), mtp/MTP 
(Mycobacterium tuberculosis pili), M.tb (Mycobacterium tuberculosis), TB 
(tuberculosis), KZN (KwaZulu-Natal), LB (Luria-Bertani), OADC (oleic acid, albumin 
dextrose and catalase), ADS (Albumin-Dextrose-Saline), DNA (deoxyribonucleic 
acid), CDS (coding sequence), ORF (open reading frame), MP (mycobacteriophage), 
PCR (polymerase chain reaction), MCS (multiple cloning site), TBE (Tris-Borate-
EDTA), SAP (shrimp alkaline phosphatase), OD (optical density) PBS-T (phosphate 
buffered saline-Tween-80), CFU (colony forming units), REMA (resazurin microtiter 
assay), AES (allelic exchange substrate), ΔDM (double mutant), gDNA (high 
molecular weight genomic DNA) 
 
Abstract: It is well established that the adhesion and invasion capacity of a bacterial 
pathogen is a major determining factor and precursor to effective host colonization and 
the onset of infection of a host. Bacterial adhesins are molecules present on the 
pathogen surface that facilitate attachment of the invading organism to the infected 
organism, and are thus vital in the host-pathogen interaction. In this study, the dual 
contribution of two of these vital adhesin proteins, HBHA (heparin binding 
haemagglutinin adhesin) and MTP (Mycobacterium tuberculosis curli pili) and their 
dual contribution to the growth, viability and biofilm production was investigated in 
M.tuberculosis (M.tb). A double mutant strain, ΔhbhA-mtp, deficient in the hbhA 
(heparin binding haemagglutinin adhesin) and mtp (Mycobacterium tuberculosis pili) 
genes was generated by phage-mediated mycobacterial specialized transduction. The 
double mutant strain was used to construct independent hbhA- and mtp- complemented 
strains. In vitro assays investigated differences in growth, viability and biofilm 
formation between the M.tb double mutant, complemented and wildtype 
F15/LAM4/KZN drug-sensitive strains. Differences in growth were measured by 
colony forming unit (CFU) counts and OD600nm readings, whilst viability was 
determined by the resazurin microplate assay. Biofilm formation was assessed by 
means of crystal violet staining to quantify cellular biomass. The findings demonstrate 
the significance of these two major adhesins in facilitating growth and biomass 
formation (to a less significant degree), but no effect on the metabolic viability of M.tb. 
The results indicate the potential of the two major adhesins, HBHA and MTP, when 
combined as biomarkers, or used as targets for novel drug and vaccine development. 
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Introduction: 
Approximately 1.67 million lives are lost to tuberculosis (TB) globally each year 
despite the availability of cheap, efficacious, and curative therapy (Bermudez et al., 
2002; Algood et al., 2003; Almedia et al., 2008; Chang et al., 2007, World Health 
Organization, 2017). A better understanding of the mechanisms utilized by 
Mycobacterium tuberculosis (M.tb) to infect the host may offer novel perspectives and 
knowledge for the potential development of effective therapeutic measures and an 
innovative, efficacious vaccine (Bermudez et al., 2002; Boggiano et al., 2017).  
 
Adhesion of bacilli to the host surface during infection is a crucial prerequisite in the 
pathogenic process, allowing for host colonization (Barbosa et al., 2006). Pathogenic 
bacteria adhere to and invade eukaryotic cells primarily to evade the immunological 
defense mechanisms mounted by the host as a means of survival, resulting in disease 
progression in the host (Cambier et al. 2014). Adherence molecules play a fundamental 
role in the pathogen-host interaction (da Silva Neto et al., 2009). Additionally, bacteria 
express numerous surface structures in order to locate their appropriate host target cells 
(Brennan et al., 2001). 
 
Specific cell-surface molecules termed adhesins, initiate close contact between a 
receptor-like domain and a ligand on the host cell surface (Gerlach & Hensel, 2007) 
and mediate bacterial adherence to host cells, facilitating both invasion of and 
colonization within the host (Chhatwal, 2002). Mycobacteria display multiple proteins 
with primary adhesin function that interact with receptors on host cells (Menozzi et al., 
2006). 
 
Fimbriae (hairs) or pili (threads) are the most commonly found form of bacterial 
adhesins, and are able to interact with glycoprotein and glycolipid receptors found on 
host cells (Esko & Sharon, 2009). Pili proteins are key hydrophobic adhesion molecules 
used by bacterial pathogens as a mechanism to initiate infection of host cells (Finlay & 
Falkow, 1997) with the adhesin tip aiding in their structural, virulence-associated 
functions (Telford et al., 2006). These include bacterial adherence and aggregation, 
colonization of mucosal surfaces and agglutination of erythrocytes (Strom & Lory, 
1993; Finlay & Falkow, 1997).  M.tb produces two physically distinct pili morphotypes: 
curli-like pili (MTP) and type IV pili (Alteri, 2005). MTP proteins are produced during 
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pathogenesis (in adherence to epithelial cells), and play a key role in stimulating the 
humoral immune response (Alteri et al., 2007). Their role as an adherence factor was 
further confirmed by Ramsugit et al. (2013) who highlighted their involvement in 
cellular aggregation and biofilm formation, as well as in the adhesion to, invasion of, 
and survival in THP-1 macrophages and A549 pulmonary epithelial cells (Ramsugit & 
Pillay, 2014; Ramsugit et al., 2016; Ramsugit & Pillay, 2019). Interestingly, MTP has 
been noted to have only a limited effect on cytokine modulation in epithelial cells 
(Ramsugit et al., 2016). Naidoo & Pillay (2017) extensively reviewed the evidence 
justifying the potential value of this major adhesin as a focus for the design of rapid TB 
diagnostics for use in low-income settings. The MTP antigen was identified as a 
suitable biomarker for a TB diagnostic test by Naidoo et al. (2018) whereby anti-MTP 
antibodies were shown to be present in the serum of HIV positive and negative patients 
with active TB. 
 
The 28-kDa heparin-binding haemagglutinin adhesin (HBHA), a major adhesin of 
M.tb, is a virulence factor reported to facilitate the dissemination of M.tb from the site 
of primary infection by initiating interaction with epithelial cells (Menozzi et al., 2006; 
Esposito et al., 2011). HBHA mutant strains showed a reduced ability to bind epithelial 
cells and disseminate from the lungs to other tissues (Menozzi et al., 2006; Esposito et 
al., 2011). The protein was demonstrated to be expressed on the bacterial surface and 
responsible for adhesion to epithelial cells and bacterial aggregation (Esposito et al., 
2011, Esposito et al., 2012). HBHA-mediated aggregation is instrumental in the 
formation of bacterial clumps, allowing for more effective adherence and invasion 
(Esposito et al., 2012).  
 
M.tb has been demonstrated to successfully adhere to, invade, and replicate within 
pulmonary epithelial cells (Bermudez & Goodman, 1996; Ashiru et al., 2010), a 
potentially safe environment for infecting bacilli to replicate away from the bactericidal 
mechanisms mounted by macrophages (Castro-Garza et al., 2002). Epithelial cells also 
present a niche within which the bacilli are afforded direct access to the host lymphatic 
and blood systems (effected by a disruption and destruction of the alveolar vascular 
endothelium), without the need for carrier macrophages (Castro-Garza et al., 2002).  
 
Given the increasing evidence supporting the role of MTP and HBHA in M.tb 
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pathogenesis, these two major adhesins in combination may potentially be a significant 
target for the design of novel, effective drugs and vaccines. In the current study, a M.tb 
mutant strain deficient in both adhesin genes, Rv3312A (mtp) and Rv0475 (hbhA), was 
constructed. The combined contribution of MTP and HBHA on growth kinetics, 
viability and biofilm production was evaluated in wildtype and double knockout mutant 
strains. Restoration of gene function in the mutant was assessed by the generation of 
complemented strains. 
 
Methods: 
 
1. Bacterial strains and growth conditions 
Bacterial strains used in the study are described in Table 1. The Dh5α Escherichia coli 
(E. coli) stocks containing the hbhA Allelic Exchange Substrate (AES) phasmids were 
grown in Luria-Bertani (LB) broth or on LB agar (Difco) for transformation, plasmid 
isolation and isolation of recombinant clones. M. smegmatis mc2155 was grown in 7H9 
(Difco) medium supplemented with 10% ADS (Albumin-Dextrose-Saline), 0.5 % (v/v) 
glycerol (Sigma, St. Louis, MO, USA) and 0.05% Tween-80. Mycobacterial strains 
other than M. smegmatis were grown in 7H9 (Difco) medium supplemented with 10% 
OADC (oleic acid, albumin dextrose and catalase), 0.5 % (v/v) glycerol (Sigma, St. 
Louis, MO, USA) and 0.05% Tween-80, or 7H10/ 7H11 (Difco) medium supplemented 
with 10% OADC. The E.coli stocks containing the hbhA and mtp Allelic Exchange 
Substrate (AES) phagemids used for specialized transduction were received from 
collaborators at the W.R. Jacobs laboratory at the Albert Einstein College of Medicine, 
the Bronx, USA. 
 
When required for selective growth, antibiotics were used at the following 
concentrations: kanamycin at 20 µg/mL for M.tb  complemented strains, and 50 µg/mL 
for E. coli; hygromycinB at 150 µg/mL for E. coli, 50 µg/mL for M. smegmatis and 75 
µg/mL M.tb mutant strains. Propagation of mycobacteriophages in M. smegmatis 
mc2155 was carried out using basal 7H10 medium supplemented with 0.4% glycerol as 
bottom agar and top agar containing 0.6% agar in 7H9 media supplemented with 0.2% 
dextrose. 
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Table 1: Bacterial strains used in this study 
 
Strain Organism Family/ 
Origin 
Drug resistance 
profile / Type 
    
Dh5α Escherichia 
coli 
Invitrogen, USA Chemically competent 
hbhA/mtp AES phagemid Escherichia coli Jacobs 
Laboratory, 
AECOM, New 
York 
hygromycinB resistant 
mc2155 Mycobacterium 
smegmatis 
Jacobs 
Laboratory, 
AECOM, New 
York 
Drug susceptible 
V9124 Mycobacterium 
tuberculosis 
F15/LAM4/KZN, 
Tugela Ferry, 
KwaZulu-Natal, 
South Africa 
Drug susceptible 
 
 
2. Construction of single and double mutant strains by specialized transduction 
In constructing the V9124 ∆hbhA-mtp double mutant strain, a marked hbhA single 
mutant strain was generated by specialized transduction as previously described 
(Bardarov et al., 2002). A high-titre phage containing a targeting gene-specific AES was 
used to remove the majority (~80%) of the hbhA coding sequence (CDS) from the 
genome of M. tuberculosis V9124 (Fig. 1). Subsequently, the single ∆hbhA mutant 
strain, was confirmed by PCR and Sanger sequencing and unmarked using the 
unmarking phage phAE280 (encoding a γδ-resolvase gene) to remove the hygromycin-
sacB cassette region of the inserted AES. The unmarked ∆hbhA strain was confirmed 
by PCR and Sanger sequencing, followed by a second round of specialized transduction 
using an mtp high-titre phage containing a targeting gene-specific AES, to construct a 
double knockout mutant. Putative ∆hbhA-mtp double mutants were confirmed by PCR 
and Sanger sequencing, and complemented using episomal plasmids to restore single 
gene function in the double mutant strain to construct 2 independent complemented 
strains. 
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2.1. Preparation of high-titre phages 
 
Plasmid DNA (kindly provided by the W.R. Jacobs Laboratory, AECOM) was 
electroporated into competent, actively growing M. smegmatis mc2155 (Larsen et al., 
2007), to select phage plaques for amplification to use in specialized transduction. 
Single plaques were used to prepare high-titre phage, harvested from plates with a lacey 
appearance (1000 plaques/plate). Additionally, a high-titre phage stock aliquot of the 
unmarking phage phAE280 (encoding a γδ-resolvase gene) was also kindly provided 
by the Jacobs laboratory. This phage targets γδ-resolvase sites flanking the 
hygromycin-sacB cassette within the AES, in order to remove this inserted fragment to 
allow for an unmarked mutant to be generated, without any additional foreign DNA. 
 
2.2. Specialized transduction 
Briefly, a log-phase culture of either V9124 (to generate the ∆hbhA single mutant) or 
∆hbhA (to generate the ∆hbhA-mtp double mutant) was washed with 
mycobacteriophage wash medium and resuspended in 1 mL mycobacteriophage (MP) 
buffer.  An equal amount of pre-warmed (37 °C to 39 °C) high-titer hbhA phage or mtp 
phage (titre ~10-10 plaque forming units) was added followed by overnight incubation 
at 37 °C. After centrifugation, pelleted samples were re-suspended in 0.2 mL 
Middlebrook 7H9 broth. The total volumes were plated onto 7H10 selective plates 
containing 75 µg/mL hygromycin and incubated for 3 to 4 weeks at 37°C.  Single 
colonies were screened by picking and patching simultaneously onto 7H10 agar plates 
with and without 75 µg/mL hygromycin. 
 
3. Mutant confirmations: 
 ∆hbhA single mutant and ∆hbhA-mtp double mutant 
High molecular weight genomic DNA (gDNA) of putative knockout mutants was 
isolated using the CTAB (NaCl-cetyl trimethylammonium bromide) method (Ausubel 
et al. 1989, Larsen et al., 2007) for all confirmations including PCR, Sanger sequencing 
and whole genome sequencing. Primers (Inqaba Biotechnology (Pretoria, South Africa) 
and Integrated DNA Technologies (Illinois, USA) were designed using Primer3 (Rozen 
and Skaletsky, 2000), with gene sequences retrieved from Tuberculist.  The primers 
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used for confirmations of the knockouts and generation of the complementation 
plasmids are listed in Table 2. 
86 
 
Table 2: Primers used for PCR confirmation, Sanger sequencing and complementation 
Gene/Amplicon Target        Forward/Left Primer Reverse/Right Primer Product 
Size (bp) 
mtp whole gene 5' CTCATGGGTCACAGCGAGTA 3' 5' ATGACAGGTTCCCTTCAAGC 3' 583 
kan (kanamycin from pJV126) 5' TTATGCCTCTTCCGACCATC 3'      5' GCCTGAGCGAGACGAAATAC 3' 223 
hyg (hygromycin from GNF phages) 5' ACCCCCCATTCCGAGGTCT 3' 5' CCGGAAGGCGTTGAGATGCA 3' 300 
sacB-up  5' CGGCAGGTATATGTGATGGG 3' use with LL-primers or hyg-out 
 
hyg-out  use with RR-primers or sacB-out 5' AACTGCTCGCCTTCACCTTC 3' 
 
Universal Uptag (GNF phages) 5' GATGTCTCACTGAGGTCTCT 3' use with LL-primers 
 
Universal Downtag (GNF phages) use with RR-primers 5' CGAGTGTCTGGTCTCGTAG 3' 
 
LL-hbhA 5' CGACATCGGCAGCTTCATCAGG 3' use with Universal Uptag primer 700 
RR-hbhA use with Universal Downtag primer 5' TGATTTCGGCGTACTGCCAGTG 3' 770 
LL-mtp 5' CCCGGCACTTGGATGCATTC 3' use with Universal Uptag primer 700 
RR-mtp use with Universal Downtag primer 5' CGGCGTCGCCAGTGGACC 3' 850 
hbhA whole gene (complementation) 5’ TTTTTTGAATTCATGGCTGAAAACTCGAACAT 3’  5’ TTTTTTAAGCTTCTACTTCTGGGTGACCTTCT 3’  624 
hbhA whole gene (sequencing) 5' CCCAACGTCCAGACCAAAGA 3' 5' GGAGTCGATGGTGATTCGGA 3' 1313 
    
  
 
 
87 
 
3.2. PCR screening of putative knockout mutants 
To confirm replacement of the target hbhA and mtp genes with the hygR-sacB cassette 
in both the single and double mutant strains, a 300bp hygromycin region from the 
inserted cassette was amplified. Putative positive mutants were also subjected to further 
PCR using gene-specific primers to confirm the loss of genes in the mutant strains. PCR 
was also carried out using the LL-Uptag combination of primers to amplify regions 
across the junction of AES insertion. A gene-specific LL forward primer and a universal 
reverse Uptag primer confirmed the placement and presence of the AES in the target 
hbhA and mtp genes when paired together (Fig.1). The relevant forward and reverse 
primer pairs were used for these confirmations as per Table 2. 
 
For all PCR analyses, standard PCR amplification was carried out in 10 µL reactions 
using the Taq DNA Polymerase dNTPack PCR reagent kit (Roche Applied Sciences, 
Germany) under the following thermocycling conditions in the GeneAmp PCR System 
9700 (Applied Biosystems): an initial enzyme activation step at 94 °C for 2 minutes, 
followed by 40 cycles of denaturation at 94 °C for 30 seconds, annealing at 50-65 °C 
for 5 seconds (specific to the primer sets used, as per Table 2) and extension at 72 °C 
for 45 seconds, with a final extension at 72 °C for 10 minutes. PCR products in Novel 
Juice DNA loading buffer and the appropriate GeneRuler DNA Ladder (Thermo 
Scientific, USA) were resolved by electrophoresis on 1.2 % (w/v) agarose in 1x TBE 
and visualized using the ChemiDoc Gel Imaging System (Bio-Rad Laboratories, USA).  
3.3. Sanger sequencing of confirmatory PCR amplicons 
PCR was carried out as described above for the purpose of Sanger sequencing using 
LL-Uptag primer pairs (described above) for the confirmation of both ∆hbhA and 
∆hbhA-mtp. Amplicons were purified using the PureLink PCR Purification kit 
(Invitrogen, USA). Briefly, the BigDye™ Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Life Technologies, USA) was used to complete termination 
reactions prior to both forward and reverse sequencing on the Applied Biosystems 
3130xl Genetic Analyzer platform using the LL- and Uptag primers used to generate 
the target amplicons. Sample preparation and sequencing was performed at the Africa 
Health Research Institute, AHRI (previously the Africa Centre for Population Studies, 
UKZN). Data was received, trimmed, a consensus sequence generated and aligned 
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against the H37Rv reference sequence (Cole, et al., 1998 - GenBank accession number 
AL123456.3) using the Geneious Pro software (V. 5.6.5).  
4. Unmarking of the ∆hbhA single mutant strain - phAE280 transduction 
The phAE280 phage (titer ~10-10 plaque forming units) was amplified, harvested as 
described above and used to unmark the confirmed V9124 ∆hbhA mutant strain by 
specialized transduction. Putative transformants were plated out onto 7H10 with 10% 
sucrose for counter-selection. Putative positive colonies (unable to grow in the presence 
of 75 µg/mL hygromycin, but able to grow in the presence of 10 % sucrose) were 
further screened by colony PCR as described above for the absence of the hygromycin 
cassette. Positive unmarked mutants were also subjected to further PCR confirmation 
using gene-specific primers to confirm the loss of genes in the mutant strains, the LL-
uptag combination of primers specific for the hbhA gene, as well as a gene-specific 
hbhA-flanking region set of primers to amplify across the whole hbhA gene and the 
flanking regions (Table 2). Sanger sequencing was also performed as described above 
using the gene-specific hbhA-flanking region primers. 
 
5. Construction of the complementation plasmid pMV261-hbhA 
The knocked-out gene (hbhA) was cloned into the pMV261 episomal vector under the 
control of the E.coli hsp60 promoter for complementation of the double mutant strain 
(Stover et al. 1991). The whole codon for the hbhA gene was amplified using primers 
incorporating EcoRI and HindIII restriction sites (Table 2) in 25 µL PCR reactions (as 
described above) using ~40 ng wild-type V9124 gDNA as a template and an annealing 
temperature specific to the primers, as per Table 2. 
After electrophoresis and purification with the QIAquick Gel Extraction Kit (Qiagen, 
USA), the PCR product and vector were double-digested with the restriction enzymes 
EcoRI and HindIII (Thermo Scientific, USA) for 1hr at 37 °C. The linearized vector 
was treated with shrimp alkaline phosphatase (SAP). The digested PCR product and 
SAP-treated vector were purified using the PureLink PCR Purification kit (Invitrogen, 
USA) before the gene was ligated into the multiple cloning site (MCS) of the linearized 
vector with T4 DNA ligase (Thermo Scientific, USA). The ligation reaction was then 
transformed by heat shock into competent Dh5α E. coli cells (Invitrogen, USA) and 
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plated for selection onto LB agar plates containing kanamycin (50 µg/mL). Plasmid 
DNA of single colonies grown in LB broth with kanamycin was isolated using the 
Qiagen Mini-Prep Plasmid Purification Kit (Qiagen, USA).  
Clones were screened by PCR amplifying and sequencing the hbhA target gene, using 
plasmid DNA and the primers used to generate the whole hbhA gene plasmid insert 
(Table 2). Putative positive plasmids were also subjected to restriction digestion of the 
purified plasmid with the restriction enzymes EcoRI and HindIII (Thermo Scientific, 
USA) to confirm the insert. Plasmids were additionally Sanger sequenced by Inqaba 
Biotechnology using primers designed by them specific to the pMV261 plasmid 
backbone. 
6. Harvesting of the pMV261-mtp complementation plasmid from the complemented 
mtp-mutant strain 
In order to obtain stock of the mtp complementation plasmid, total gDNA was isolated 
as above from the M.tb V9124 complemented mtp-mutant (Ramsugit et al. 2013), and 
subject to plasmid purification using the Qiagen MiniPrep Plasmid Purification kit 
(Qiagen, USA). Purified samples were quantified and confirmed by gel electrophoresis 
as described above. Samples were transformed into competent Dh5α E.coli cells 
(Invitrogen, USA) and plated on LB agar plates containing the selective antibiotic 
kanamycin at a concentration of 50 µg/mL. Individual single colonies were grown in 
LB broth with kanamycin, and plasmid DNA was isolated using the Qiagen Mini-Prep 
Plasmid Purification Kit (Qiagen, USA).  Clones were screened by PCR using plasmid 
DNA, kanamycin-targeting primers and the primers used to generate the mtp insert 
(Table 2).  
7. Complementation of ∆hbhA and ∆hbhA-mtp mutants with their respective genes 
to confirm restoration of gene function 
 
Mutant strains were electroporated with plasmid constructs as per Larsen et al. (2007). 
Electroporated cells were selected for on 20 µg/mL kanamycin-containing 7H11 agar 
plates, following which single colony transformants were inoculated into 7H9 liquid 
media, and screened by colony PCR (as described above) for the presence of the 
kanamycin resistance cassette and the target genes (either hbhA or mtp). 
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8. In vitro growth kinetics (OD600nm, CFU count, REMA viability assay) 
 
Aliquots (500 µL) of a stock culture stored at an OD600nm of 1, equivalent to ~1 X 10
8 
cells/mL (Larsen et al., 2007), were inoculated into 50 mL of 7H9 broth (supplemented 
with 10 % OADC, 0.05 % Tween-80 and 0.5 % glycerol). After growth with shaking 
at 37 ºC for 6 to 8 days, cultures at an OD600nm of 1.6-1.8 were centrifuged at 3000 RPM 
for 10 minutes. The pellet was washed twice with 8 mL of PBS-T at 4000RPM for 10 
minutes and re-suspended in 1 mL of supplemented 7H9 broth. The culture was back 
diluted to an OD600nm of 0.015 in 25 mL of supplemented 7H9 broth in triplicate and 
grown with shaking at 37ºC for 30 days for measurements for OD600nm, CFU counts 
and metabolic activity (resazurin microtitre assay) at baseline & every 3rd day over a 
21-day incubation at 37 ºC. All assays were performed in triplicate for technical and 
biological repeats. 
 
OD readings were measured in triplicate using a spectrophotometer (Biochrom WPA 
Lightwave II, Labotec) at a wavelength of 600 nm.  CFU counts were performed by 
plating out 100µL of a 10-fold serial dilution of culture in triplicate on 7H11 plates 
containing 10 % OADC and 0.5 % glycerol. Colonies were counted after incubation at 
37 ºC for approximately 21-25 days. 
 
Viability was evaluated by quantifying the metabolic activity of 100µL of broth culture 
using the resazurin microtiter assay (REMA) in a 96-well microtitre plate in triplicate. 
The blank negative control was 100 µL broth. After the addition of 15 µL of a 0.02 % 
resazurin solution (Sigma-Aldrich, USA), the plate was incubated overnight at 37 °C 
and OD readings measured at 600 nm in a GloMax®-Multi Detection System 
absorbance spectrophotometer (Promega Corp., USA). 
 
9. Crystal violet quantification of biofilm formation 
Strains were grown to OD600nm 1 and diluted 1:100 (v/v) in Sauton’s minimal medium. 
A suspension of 2 mL was cultured for biofilm growth in 24-well plates incubated at 
37 °C in 5 % CO2 for 5 weeks without shaking. Following incubation, the spent media 
was carefully aspirated to prevent disturbance of the biofilm layer, and the dried cell 
biomass was allowed to air dry in the biosafety cabinet. Individual wells were incubated 
with 0.5 mL of 1 % crystal violet solution for 10 minutes. Wells were washed three 
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times with deionized water and the biomass was allowed to dry, following which 2.5 
mL of a 95 % ethanol solution was added to each well. Wells were incubated for 10 
minutes and the absorbance of the aspirate was measured at A600 in a GloMax®-Multi 
Detection System absorbance spectrophotometer (Promega Corp., USA). All assays 
were performed in triplicate for both technical and biological repeats. 
 
10. Statistical analysis 
All experiments were performed in independent triplicate biological experiments with 
triplicate technical repeats. Data were analyzed by one-way Analysis of Variance 
(ANOVA), with the statistical analysis performed using SPSS 25.0 statistical software, 
and a p-value less than 0.05 considered significant. Error bars represent the standard 
error of the mean (SEM) of these triplicate biological and technical repeats. 
 
Results: 
1. Confirmation of the hbhA single mutant, ∆hbhA 
 
Positive hbhA single mutant strains were purified and unmarked as described above to 
generate gene organization as per Fig. 1 A. High molecular weight gDNA was extracted 
and used to carry out the PCR for the hbhA LL-uptag fragment and the hyg target in the 
AES to confirm the partial removal of the hbhA gene (Fig. 2 A and B respectively).  
Sanger sequencing was performed on putative unmarked hbhA mutant strains using 
flanking region primers to generate a 1313bp hbhA whole gene amplicon (Fig. 3 A).  
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Fig. 1: Gene organization maps of double gene knockout mutants indicating the resulting allelic 
exchange replacement in the ORFs. A. The unmarked hbhA forward direction gene 
arrangement and B. The marked mtp reverse direction gene arrangement, specific to the double 
hbhA-mtp mutant. Maps indicate respective flanking regions, regions of gene deletion and sites 
important to primer design for confirmation and unmarking techniques. 
 
 
2.  Construction and confirmation of the hbhA-mtp mutant strain, ∆DM 
 
Specialized transduction of the unmarked V9124 hbhA single mutant strain with a 
phAE159 shuttle phasmid carrying an mtp AES was performed as described by 
Bardarov et al. (2002) to generate gene organization depicted in Fig. 1 B. Transduced 
cells were plated onto hygromycin selective media and colonies were screened by PCR 
for the presence of multiple regions to confirm the insertion of the AES cassette.  
 
Amplification of the hbhA LL-uptag fragment and the mtp LL-uptag confirmed the 
partial removal of the hbhA and mtp genes (Fig. 2 C and D respectively). 
 
The LL-uptag primer sets amplified a region spanning the left flanking arm and a region 
upstream of the AES hyg-sacB cassette. The hbhA LL-uptag and the mtp LL-uptag 
primer sets were used to amplify regions showing the presence of the AES that was 
inserted into the genome at the specific regions (in the hbhA CDS and mtp CDS 
respectively), thus indicating the generation of a hbhA-mtp double mutant strain. These 
PCR’s both served to confirm the hbhA-mtp double mutant. 
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Amplicons for PCR positive strains were purified and subjected to Sanger sequencing 
which further confirmed the double mutant strain (Fig. 3 B and C). Additionally, gDNA 
was subject to whole genome sequencing by our collaborators at the William R. Jacobs 
laboratory at AECOM on the Illumina MiSeq platform confirming Sanger sequencing 
results (data not shown). 
 
 
Fig. 2: PCR confirmation of hbhA single and hbhA-mtp double knock out mutant strains.  A. 
770bp hbhA LL-uptag amplicon indicates the ∆hbhA single mutant in 3 putative colonies B. 
300bp hyg amplicon confirms the 3 putative colonies as ∆hbhA single mutant strains. C. 770bp 
hbhA LL-uptag amplicon indicates the presence of the hbhA AES in 3 putative ∆hbhA-mtp double 
mutant strains; D. 700bp mtp LL-uptag amplicon indicates the presence of the mtp AES in 3 
putative ∆hbhA-mtp double mutant strains. Frames C & D together confirm the generation of the 
∆hbhA-mtp double mutant, ∆DM. 
 
 
Fig. 3.: Sanger sequencing alignment confirmation. The H37Rv whole genome was used as a 
reference strain to align purified sequenced PCR amplicons against. Alignment of the 
amplicons agains the correct regions and loci serves as confirmation of unmarking or deletion 
of genes. A.1313bp hbhA whole gene amplicon sequencing confirms phAE280 unmarked hbhA 
mutant. B. 770bp hbhA LL-uptag amplicon confirms presence of the remaining section of the  
hbhA AES (post-unmarking) in the double mutant. C. 700bp mtp LL-uptag amplicon confirms 
mtp absence in the double mutant. 
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3. Complementation of double mutant 
 
3.1.Construction of the complementation plasmid pMV261-hbhA 
 
To complement and restore the expression of the hbha gene in the mutant strains, the 
whole gene CDS of hbhA was ligated into the MCS of the episomal expression plasmid 
pMV261, and transformed into competent E.coli Dh5α cells. Plasmids isolated from the 
resultant transformants on kanamycin selective media, were screened using restriction 
digest (EcoRI and HindIII), PCR and Sanger sequencing. Figure 4A confirms the 
insertion of the hbhA whole gene into the pMV261 plasmid backbone by restriction 
digest. Confirmed plasmids were then subject to PCR using the primers initially used 
to amplify the whole hbhA gene. Forward and reverse Sanger sequencing of these 
positive amplicons was performed to confirm the whole gene insert were present in the 
plasmid pMV261-hbhA (Fig. 4B). 
 
 
Fig. 4: Complementation of the hbhA-mtp ∆DM with pMV261-hbhA and pMV261-mtp A. Three 
positive clones of pMV261-hbhA confirmed by EcoRI-HindIII restriction digest. B. Positive 
clone of pMV261-hbhA confirmed by Sanger sequencing alignment against the H37Rv whole 
genome as a reference strain. Alignment of the amplicons against the correct regions and loci 
serves as confirmation of the correct gene being inserted into the plasmid backbone for gene 
expression. C. Presence of the 223bp kanamycin cassette amplicon confirm successful 
electroporation of the ∆hbhA-mtp double mutant, ∆DM, by pMV261-hbhA (lanes 1-3) and 
pMV261-mtp (lanes 4-6). 
 
 
3.2. Generation of complemented double mutant strains 
 
Mutant strains were electroporated with the pMV261-hbhA (described above) and 
pMV261-mtp plasmid (Ramsugit et al., 2013) constructs as per Larsen et al. (2007). 
PCR was performed on single colony transformants to screen for the presence of the 
kanamycin resistance cassette (Fig. 4C), confirming successful complementation of the 
hbhA-mtp double mutant strain with either pMV261-hbhA or pMV261-mtp. 
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4. HBHA and MTP significantly impact in vitro growth kinetics but not viability 
 
4.1. HBHA and MTP contribute jointly to in vitro growth of wildtype V9124 strain  
 
OD600nm measurements demonstrated significant differences among the strains across 
the 21-day period (p < 0.01) with the WT strain showing consistently the highest growth 
at all intervals (Fig. 5 A). Although the collective differences in growth was statistically 
significant [F (5,12) = 46.601, P < 0.01], the major significance was seen when 
comparing V9124 to any of the strains. The ΔDM showed significant growth 
differences relative to the complemented strains from day 12 onward (p <0.05). 
 
No significant differences were seen in the CFU/mL among all the strains on day 0, in 
contrast to the significant differences noted between ∆DM and WT on day 3 (p = 0.006) 
and day 6 (p=0.003) (Fig. 5 B).  Significantly higher growth of the WT (p = 0.00) 
relative to all the strains was observed from day 9 to 21, and between ∆DM and the 
complemented strains on day 21 (p < 0.01). 
 
4.2. HBHA and MTP do not affect viability of V9124 strain  
 
REMA showed overall viability did not differ significantly among strains (Fig. 5 C). 
On day 6 however, the viability of the ΔDM mtp-complement was significantly higher 
(mean 1.560 ± 0.05604; p=0.041) in comparison to the ΔDM. The viability of the ΔDM 
and complemented strains on day 21 was significantly increased relative to the WT 
V9124 (p < 0.05). 
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Fig. 5.: Growth kinetics & viability assay: optical density measured at 600 nm, colony forming units by serial dilution plate out, and metabolic viability 
determination by rezasurin (Alamar Blue dye) reduction. Error bars are indicative of the standard error of the mean (SEM) for triplicate technical and 
biological repeats. V9124 wildtype strain was grown alongside the hbhA-mtp double mutant (ΔDM) and the complemented strains (ΔDM-hbhA comp; 
ΔDM-mtp comp) over 21 days. Growth measurements were captured every 3rd day and data were analyzed by one-way analysis of variance (ANOVA) 
using SPSS 25.0 statistical software. A. Optical density measurements at OD600nm indicate a significant (p<0.05) difference in the growth of the double 
mutant relative to the growth of the wildtype strain. Growth was recovered by ~50 % when the double mutant was complemented to restore individual 
genes. B. CFU counts indicate a significant (p<0.05) difference in the growth of the double mutant relative to the growth of the wildtype strain after 
timepoint 2. Growth was recovered slightly when the double mutant was complemented to restore individual gene function. C. The REMA assay was 
performed to establish viability, and indicated no significant (p>0.05) differences in the viability of the double mutant relative to the wildtype strain 
over the 21-day period. 
 
 
97 
 
3.4. Biofilm assay: Biomass quantification by crystal violet staining  
 
Fig. 6: Biofilm production assessed in mutant and complemented strains by relative 
quantification of biomass production. The V9124 wildtype strain was grown alongside the 
hbhA-mtp double mutant (ΔDM) and the complemented strains (ΔDM-hbhA comp; ΔDM-mtp 
comp). The data were analyzed by one-way analysis of variance (ANOVA) using SPSS 25.0 
statistical software; F (5,12) = 3.582, P < 0.05. Error bars are indicative of the standard error of 
the mean (SEM) for triplicate technical and biological repeats. 
 
Crystal violet quantification of biofilm production demonstrated an 8.82% reduction by 
the ΔDM and 9.3% reduction by the ΔDM hbhA complemented strains relative to 
V9124 (Fig. 6). Even though these differences did not vary enough in the mutants 
relative to the wildtype strain to warrant any significance, MTP does appear to play 
more of a role than HBHA in biofilm formation, with the mtp complemented double 
mutant showing only a 5.6% reduction relative to the V9124 wildtype strain. 
 
Discussion: 
 
The presence of adhesins on the bacterial surface is crucial to the survival of pathogenic 
strains, as these molecules are fundamental in instigating and perpetuating host-
pathogen interaction (Solanki et al., 2018). The ability to specifically target the initial 
interaction between host and pathogen in order to prevent infection holds great promise 
for the identification of novel biomarkers for rapid TB diagnostic tools, drugs and 
vaccine development. Therefore, there is a need to fully characterise the function of the 
proteins/putative proteins that have been identified to play a role in this primary contact, 
as this area of study is still relatively in its infancy. 
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Amongst the several adhesins (Díaz-Silvestre et al., 2002; Kinhikar et al., 2006; Alteri 
et al., 2007; Ragas et al., 2007; Hickey et al., 2010; Kumar et al., 2013; Esparza et al., 
2015) identified in M.tb, two molecules, HBHA (Pethe et al., 2001) and MTP (Alteri et 
al. 2007, Ramsugit et al., 2013) have emerged as significant potential biomarkers that 
may be targeted for intervention strategies. Therefore, using functional genomics, this 
study attempted to quantify the combined contribution of these genes in growth 
kinetics, viability and biofilm formation, by comparing with a double hbhA-mtp 
knockout mutant (∆DM) and complemented strains against the wildtype V9124 M.tb.  
 
The functional copies of the genes encoding the two major adhesin molecules, Rv0475 
(hbhA) and Rv3312A (mtp), were knocked-out of V9124 successively using the phage-
mediated method of mycobacterial specialized transduction (Larsen et al., 2007). 
Approximately 80% of the coding sequences of these two genes were removed from 
the genome, rendering the encoded proteins non-functional in the ∆DM strain. To 
quantify the relative contribution of each adhesin, hbhA and mtp complemented strains 
were separately constructed in ∆DM. A complementation plasmid was created to 
express hbhA episomally, whereby the whole hbhA gene was ligated downstream of the 
hsp60 promoter in the episomal Kan+ plasmid, pMV261, and electroporated into ∆DM. 
Thereafter, the mtp complementation plasmid pMV261-mtp (extracted from the 
complemented Δmtp mutant strain previously generated by Ramsugit et al., 2013), was 
electroporated into ∆DM to generate an mtp-complemented strain.    
 
The outcomes of the growth assays, by means of OD600nm quantification and CFU 
counts suggests that HBHA and MTP in concert, significantly contribute to growth of 
M.tb. Moreover, growth of the independently complemented double mutant strains 
suggests that this contribution is approximately equal for each adhesin. 
 
The in vitro data also revealed that whilst the growth rate was significantly impaired, 
the double mutant strain remained metabolically viable compared to the wild type and 
complemented strains, suggesting that HBHA and MTP do not play a role in the 
metabolic activity of M.tb.  However, the REMA assay may not be sensitive enough to 
show this conclusively, and a more definitive test is required. It is possible that 
variability in the data could be due to this lack of sensitivity, when measurements are 
performed much later during the growth cycle. This may be due to the larger numbers 
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of bacterial cells present in the wild type compared to the mutant and complemented 
strains. 
 
Formation of biofilms, which are known to increase antibiotic resistance and reduce 
clearance from the host, is regarded as being highly dependent upon expression of 
bacterial adhesion molecules (Stones and Krachler, 2015). Although no statistically 
significant differences were seen between the different strains in terms of biomass 
formation, the removal of hbhA and mtp concurrently caused an 8.82% reduction in 
biomass relative to the wild type V9124. The notable reduction in biomass of the ΔDM 
hbhA complemented strain that still harboured the mtp gene, and the lower, insignificant 
reduction by the ΔDM mtp complemented that retained hbhA relative to V9124 support 
the findings by Ramsugit et al. (2013), and suggest that MTP may potentially have a 
greater effect on biofilm formation that HBHA. Variability in the degree of biomass 
reduction presented in the two studies is notably high, however, this may be attributed 
to the effect of restoring a major adhesin with an episomal plasmid. This may not be 
enough to appropriately regulate the expression pathways responsible for control of 
compensatory mechanisms that may have been switched on in the double mutant, with 
a loss of gene function. Upregulation of other genes may also interfere with the 
feedback mechanisms to produce unexpected phenotypes and a ripple effect on 
regulation pathways. Pathway analysis and additional studies using the double and 
single mutants to establish biomass and viability are thus valuable in painting a true 
picture of why there may be discrepancies between the two studies, and if this is indeed 
the case. 
 
The study outcomes indicate the key pathogenic importance of the two major M.tb 
adhesins in promoting in vitro growth of the F15/LAM4/KZN susceptible strain. These 
results suggest the significance of the two adhesins in combination as biomarkers for 
the development of potential diagnostic interventions. Treatment strategies targeting 
multiple adhesins may prove most beneficial to incapacitating the pathogen, as the 
simultaneous absence of these adhesins may prevent the pathogen from entering the 
cell, thereby restricting their ability to multiply successfully, resulting in a potential for 
reduced growth capacity, in vivo. Adjunctive therapy with blocking antibodies to 
prevent bacilli entry into the cell may also serve to boost efficacy of the current first 
line drugs. 
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Although the general conceptual appeal of a targeted blocking antibody in vaccine 
development remains popular, anti-adhesion therapies are still not commonly utilized 
in the treatment of bacterial infections. This is due to the expression of multiple 
adhesion molecules in a well-modulated time- and tissue-specific manner over the 
course of an infection (Stones and Krachler, 2015). Additionally, bacteria are able to 
initiate compensatory mechanisms to circumvent the effects of a loss of expression of 
key genes, and possess a host of molecules that either have moonlighting function as 
adhesins outside of their core functions (Govender et al., 2014), or work via tributary 
pathways to facilitate entry into the host (e.g. host scavenger receptors, host 
complement receptors and host Fe receptors) (Zimmerli et al., 1996). However, a large 
portion of the M.tb genome encodes hypothetical proteins that have yet to be studied 
and functionally characterized (Mazandu & Mulder, 2012), making it most likely that 
the organism possessed genes encoding novel factors that hold roles in host cell 
adherence that are still unidentified (Mann et al., 2016). The presence of the large 
number of predicted adhesins (as reviewed in Govender et al., 2014) raises the further 
issue of redundancy and functional duplication, a potential confounding factor in gene 
knockout studies. This study highlights the usefulness of targeting multiple adhesins as 
a way to effectively counteract this pitfall.  
 
In generating the double mutant, the study was able to illustrate a potential compounded 
effect caused by a loss of function of two major adhesins on bacterial growth. A 
limitation of this study design was the independent complementation of the double 
mutant strain by the single genes in episomal expression plasmids. This resulted in 
incomplete complementation of both hbhA and mtp together in ∆DM to fully restore 
gene function. The motivation for generating these individual single complemented 
∆DM strains was to attempt to evaluate the individual contribution of each adhesion 
molecule in the assays done, to establish if one gene had variable or increased effects 
on growth, viability and biofilm formation over the other.  
 
Even though the outcomes of these experiments allude to the contribution toward 
growth phenotypes being approximately equal for each adhesin, it must be considered 
that a number of factors could have impacted the effective complementation of the 
double mutant, such as transcriptional errors in the development of the expression 
plasmid or reduced activity of the plasmid promoter. However, in order to fully 
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understand the combined effect of these genes together, further studies utilizing a 
double-complemented hbhA-mtp mutant strain are needed as a supplementary step to 
substantiate and truly validate the outcomes of this study, to see the full restoration of 
gene function when both genes are complemented. 
 
Further studies looking into the impact of the absence of these genes on signaling 
pathways and gene regulation networks (both in M.tb and the host) would shed more 
light into the role they play in facilitating bacterial proliferation, and the potential effect 
that they may have on host immune modulation. They may also serve to indicate 
potential compensatory genes and mechanisms (for example, those highlighted in 
Zimmerli et al., 1996) to be considered as novel therapeutic targets for development 
alongside hbhA and mtp.  
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The second paper evaluated the potential importance of HBHA and MTP as a combined target 
for therapeutic drug and vaccine development by establishing the in vitro growth, viability and 
biofilm formation capacity. 
 
A novel double mutant strain deficient in both the hbhA and mtp genes was generated in the 
susceptible F15/LAM4/KZN M. tuberculosis strain V9124, and single gene complemented 
strains were then derived. Growth assay data showed the concurrent removal of both major 
adhesin genes results in a dramatically significant reduction in growth, while cellular viability 
and biofilm formation remained unaffected. This confirmed the potential novel efficacy of 
targeting hbhA and mtp and their protein counterparts HBHA and MTP for drug and vaccine 
development. 
 
Following from this, the next paper aimed to further establish the contribution of these two 
protein molecules to the in vitro adhesion to and invasion of A549 pulmonary epithelial cells. 
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Abstract: 
Novel targets are urgently sought for the development of therapeutic interventions to 
reduce high global TB burdens. Several studies have demonstrated the importance of 
the two primary M. tuberculosis (M.tb) adhesins, the heparin binding haemagglutinin 
adhesin (HBHA) and the M.tb curli pili protein (MTP) independently in pathogenesis, 
suggesting that they may be suitable biomarkers for this purpose. This study aimed to 
elucidate the role of the two adhesins simultaneously in the host –pathogen interaction. 
Adhesion and invasion assays were performed in A549 pulmonary epithelial cells 
infected with a previously constructed, double knockout mutant Δhbha-mtp (∆DM) 
M.tb strain, single gene (ΔDM-hbhA and ΔDM-mtp) complemented and the wild-type 
strain V9124. A significant reduction in adherence to A549 pulmonary epithelial cells 
(81%) was seen in the ΔDM strain relative to V9124 (p = 0.00), while the invasive 
ability of this mutant strain was reduced by 83% (p = 0.00). Complementation with 
hbhA partially restored adhesion to 45% and invasion to 29% relative to V9124, while 
complementation with mtp partially restored adhesion to 43% and invasion to 40% 
relative to V9124. Both adhesins thus play a significant role in adhesion and invasion, 
with MTP having a potentially greater invasin role than HBHA in the F15/LAM4/KZN 
susceptible strain V9124. HBHA and MTP appear to be similar in their role as adhesins. 
Their major roles in the overall adhesion-invasion capacity of M.tb thus suggests that 
these two molecules, in combination, present an attractive option as novel targets for 
potential vaccine/drug development. 
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Introduction: 
Tuberculosis (TB) remains a high burden disease globally, with a low likelihood to 
reach the specific targets set out in the End TB Strategy (including a 90% reduction in 
TB deaths and an 80% reduction in new TB cases per year, by 2030) (WHO, 2017). 
The ability of Mycobacterium tuberculosis (M.tb) to adhere to and infect host cells is 
core to the success of this pathogen in evading immune responses, resulting in one of 
the most debilitating diseases known to man. Whilst TB continues to result in 
approximately 1.67 million worldwide (WHO, 2017), our knowledge regarding the 
biology and genetics of the causative organism remains inadequate to effectively 
reverse this trend. The rapid escalation in the number of M.tb infections (an estimated 
10.4 million new TB cases globally during 2016, as per the WHO Global Report 2017), 
facilitated by a lack of rapid point of care (POC) diagnostic tests, high prevalence of 
HIV-TB co-infections, together with the emergence of multi-drug-resistant strains, has 
fast-tracked the search for novel biomarkers and drug targets in order to reduce the high 
TB burdens. 
  
The currently implemented Bacillus Calmette-Guérin (BCG) vaccine was developed 
almost 100 years ago and has been shown to prevent severe forms of TB in children. 
However, no vaccine currently exists with efficacy in preventing TB disease in adults, 
either pre- or post- exposure to TB infection (WHO, 2017). There is an urgent need for 
development of an effective vaccine, as well as innovative, efficacious drugs with 
sterilizing ability, to shorten the current duration of treatment and reduce the risk of 
patient non-compliance and relapse (Betts, et al., 2002; Krieger et al., 2012; Gaur & 
Mishra, 2017). Functional genomics studies are crucial in the validation of novel 
pathogen-specific drug targets for the development of effective new therapies 
(Bellinzoni & Riccardi, 2003). As with many pathogenic micro-organisms, adhesion of 
the infecting agent to the host surface is thought to be a crucial prerequisite in the 
pathogenic process of TB infection, allowing for host colonization (Espitia et al., 2012). 
This process is mediated by adhesin molecules (amongst others) present on the 
microbial surface, which serve to recognize and bind receptors on specific host cells 
(Nizet et al., 2017). 
 
The host pulmonary epithelial cells are considered as the initial barrier faced by M.tb. 
upon entry into the human host, due largely to the abundance of epithelial cells in the 
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lung (Crandall and Kim 1991; Pessolani et al., 2003; Adlakha et al. 2012; Sarkar et al., 
2016). Although the interaction between M.tb. bacilli and the lung epithelial cells has 
largely been overlooked until recently (Harriff et al., 2014), invading bacilli potentially 
have a greater chance of infecting these cells rather than macrophages, given their 
relative abundance within the alveolar space (Crandall and Kim 1991; Pessolani et al., 
2003). Additionally, bacilli have a greater chance of survival within epithelial cells than 
in the harsh environment presented by the presence of unarrested phagosomes within 
the macrophage cytoplasm. These cells provide a potentially optimal niche within 
which the host-adapted pathogen can readily replicate if they are able to successfully 
evade and circumvent the host defences and immune responses (Falkow, S., 2006; 
Cambier et al., 2014). This is possible since they are afforded direct access to the host 
lymphatic and blood systems (without the need for carrier macrophages) upon 
disruption and destruction of the alveolar vascular endothelium (McDonough and 
Kress, 1995; Dobos et al., 2000; Castro-Garza et al., 2002).  
Mycobacteria display multiple proteins with primary and secondary adhesin function 
that interact with host cell receptors (Menozzi et al., 2006). The primary adhesin in M.tb 
is a 28-kDa heparin-binding haemagglutinin adhesin (HBHA), a virulence factor that 
facilitates the dissemination of M.tb from the site of primary infection by initiating 
interaction with epithelial cells (Menozzi et al., 2006; Esposito et al., 2011). 
Extrapulmonary dissemination of bacilli is essential to the development of active TB 
infection (Yang & Kong, 2015; Polena et al., 2016). The protein is localized to and 
expressed on the surface of the bacteria, and is primarily responsible for adhesion to 
epithelial cells (Esposito et al., 2011). Mutant strains deficient in functional copies of 
hbhA show a reduced ability to bind epithelial cells and disseminate from the lungs to 
other tissues (Menozzi et al., 2006; Esposito et al., 2011).  
The two physically distinct M.tb pili adhesin morphotypes (curli-like pili (MTP) and 
type IV pili) are produced during pathogenesis and play a key role in adherence to 
epithelial cells, in turn stimulating the humoral immune response (Alteri et al., 2007). 
Ramsugit et al. (2013) highlighted this role as an adherence factor, confirming the 
involvement of pili proteins in cellular aggregation and biofilm formation. Ramsugit & 
Pillay (2014) additionally established the role of MTP in the adhesion to and invasion 
of THP-1 macrophages (Ramsugit and Pillay., 2014) and A549 pulmonary epithelial 
cells (Ramsugit et al., 2016), as well as in modulating immune response in epithelial 
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cells (Ramsugit et al., 2016). MTP is considered crucial in mediating close interaction 
and colonization with host lung epithelial cells (Alteri et al., 2007). The current study 
undertook to assess the combined in vitro effect of MTP and HBHA in the adhesion to 
and invasion of A549 pulmonary epithelial cells, by infection with a double knockout 
mutant Δhbha-mtp M.tb strain. 
Methods: 
Bacterial strains 
The combined potential of HBHA and MTP proteins as epithelial cell-associated 
adhesins and invasins of M. tuberculosis was investigated using a novel double gene 
knock-out mutant strain, Δhbha-mtp (ΔDM), generated by phage-mediated specialized 
transduction of allelic exchange substrates (Govender et al., unpublished). 
 
Briefly, the mtp gene was disrupted by mycobacterial specialized transduction using 
phage-packaged allelic exchange substrates (AES) in a confirmed unmarked hbhA 
mutant strain, Δhbha::γδsacBhygγδ (Δhbha) in M.tb V9124, a drug susceptible clinical 
strain of the F15/LAM4/KZN family (Govender et al., unpublished). Additionally, 
single gene complemented strains, ΔDM-hbhA complement and ΔDM-mtp 
complement were also generated by electroporation of episomal plasmids expressing 
the individual genes into the double mutant strain (Govender et al., unpublished). 
Strains were cultured in Middlebrook 7H9 medium (Difco, Detroit, MI, USA) 
supplemented with 10 % (v/v) OADC (oleic acid-albumin-dextrose-catalase) 
enrichment (Becton Dickinson, Sparks, MD, USA), 0.5 % (v/v) glycerol (Sigma, St. 
Louis, MO, USA), and 0.05% (v/v) Tween 80 (Sigma) and incubated with shaking (130 
RPM) at 37 °C for 10-12 days to an OD600nm ~0.8-1.0.  
 
Adhesion and Invasion Assays 
The methods were performed as described by Ramsugit et al. (2016).  A549 adherent 
hypotriploid human pulmonary epithelial cells (ATCC® CCL-185™) were cultured in 
75 mL vented tissue culture flasks in 20mL MEM Eagle (EMEM) with Earle's BSS, 
with L-glutamine (Lonza, Rockland, ME, USA) containing 10 % v/v heat-inactivated 
foetal bovine serum (FBS) (Gibco, USA), under 5 % CO2 at 37 °C to confluency. 
Twenty-four well plates (NEST Biotechnology, China) were seeded at a density of 5 × 
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105 cells to ensure a multiplicity of infection of 5:1 after trypsinized confluent cells 
were pooled and washed. Prior to infection, confluent cells in seeded plates were 
repeatedly washed with 1 mL 1x phosphate-buffered saline (PBS) (Oxoid, Hampshire, 
UK) to remove any non-adherent A549 cells and residual media, followed by the 
addition of 1mL fresh tissue culture medium. 
 
Log phase bacterial cell cultures were pelleted at 2,000 × g for 20 min at 20 °C (Heraeus 
Multifuge 3S-R Centrifuge; Thermo Scientific, Germany) and resuspended in 10mL 
fresh tissue culture media. Pulmonary epithelial cells were infected in triplicate with 
wildtype, mutant and complemented bacterial strains at a multiplicity of infection of 
5:1. Plates were incubated at 37 °C with a constant 5 % feed of CO2 for either 1 hour 
(adhesion assay) and 2 hours (invasion assay) post-infection. To confirm accurate 
bacterial counts were used for infection, serial dilutions of the bacterial suspensions 
were plated in triplicate onto 7H11 agar plates to establish the CFU. Uninfected 
epithelial cell controls were included in all assays.  
 
Following the respective incubation periods for the adhesion and invasion assays, the 
spent infection medium was aspirated and wells were washed three times with 1 mL 
sterile PBS. Amikacin (300 mg/mL; Sigma) was then used to treat the invasion assay 
plate, followed by incubation for 1 hour at 37 °C in 5 % CO2. Subsequent killing of any 
adherent extracellular bacteria in the invasion assay was confirmed by plating serial 
dilutions of the amikacin-containing media onto 7H11 plates and enumerating CFUs 
after 3 weeks. Following incubations for both assays, cells were washed in triplicate 
with 1 mL 1x PBS, and 1 mL 0.1 % Triton X-100 (Sigma) was added to each well. 
Plates were incubated for 20 minutes to allow lysis of adherent A549 cells. The cell 
lysates were serially diluted in PBS, plated in triplicate onto 7H11 agar plates, and 
incubated at 37 °C in 5 % CO2
 for 3 weeks to determine the number of adherent or 
invading bacteria.  
 
The degree of adhesion or invasion was determined as a percentage and calculated as: 
(colony-forming units (CFU) of the attached or invaded bacteria/CFU of the added 
bacteria) × 100. A relative percentage of adhesion to or invasion of the mutant and 
complemented strains was subsequently reported as: (% adhesion to or invasion of 
mutant or complemented strain/% adhesion to or invasion of the wild-type) × 100. All 
113 
 
experiments were performed in independent triplicate biological experiments with 
triplicate technical repeats. Data were analyzed by one-way Analysis of Variance 
(ANOVA), with the statistical analysis performed using SPSS 25.0 statistical software, 
and a p-value less than 0.05 considered significant. 
 
 
Results: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The role of M. tuberculosis heparin-binding haemagglutinin adhesin (HBHA) and curli 
pili protein (MTP) in the adhesion to (A) and invasion of (B) A549 pulmonary epithelial cells. 
Cells were exposed to V9124 wild-type, ΔhbhA-mtp double mutant (ΔDM) and complemented 
strains (DMHC – double mutant hbhA complement; DMMC – double mutant mtp complement) 
for 1 hour (adhesion assay) and 2 hours (invasion assay) at 37°C. Results are depicted as the 
percentage adhesion or invasion of the mutant and complemented strain, relative to V9124 as 
the control. Error bars indicate the calculated ±SEM relative to the calculated mean of 3 
biological and triplicate technical repeat experiments. Data were analyzed by one-way analysis 
of variance (ANOVA) using SPSS 25.0 statistical software (Adhesion assay - F (3,8) = 370.82, 
p < 0.00; Invasion assay - F (5,12) = 859.36, p < 0.00). 
 
 
The ability of the ΔhbhA-mtp double mutant strain (ΔDM) to adhere to A549 
pulmonary epithelial cells was significantly reduced by 81 % relative to the wild-type 
strain V9124 (p = 0.00) (Fig. 1A). The invasive ability of the mutant was also reduced 
by 83 % (p = 0.00) (Fig. 1B).  
 
Adhesion and invasion rates were partially restored by complementation of the 
individual genes independently with the pMV261 expression vector containing either 
an mtp or hbhA whole gene insert (Govender et al., unpublished). Complementation 
with plasmid pMV261-hbhA resulted in a phenotype of partially restored adhesion 
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capacity to 45 % and invasion capacity to 29 % relative to the wildtype strain (Fig. 1 A 
and B). Complementation with plasmid pMV261-mtp restored mtp expression and 
resulted in partially restored adhesion to 43 % and invasion capacity restored to 40 % 
relative to the V9124 wildtype strain (Fig. 1A and B). However, even though the 
adhesion and invasion capacity of both the complemented mutant strains remained 
significantly less than the wildtype (p = 0.00), there was no significant difference in the 
adhesion capacity of the hbhA-complemented mutant when compared to the mtp-
complemented mutant (p = 0.855), while the invasion capacity between the two strains 
differed significantly (p = 0.00).  
 
Discussion: 
Infection by M. tuberculosis is regulated by a range of factors, and involves complex 
interaction between the host immune system and the bacilli. The mechanism of 
bacterial adherence to its target tissues is considered as fundamental to the infectious 
process (Finlay & Falkow, 1997). To establish an active infection, bacteria express 
adhesins (specialized surface proteins) that mediate adhesion to the host cells and 
prevent clearance (Niemann et al., 2004). Mycobacterial adhesins that engage with 
pulmonary epithelial cells may play a fundamental role in the infection process, due 
largely to these cells most likely being involved in the initial interaction with the host 
(Pethe et al., 2001). Identifying and characterizing key adhesin molecules involved in 
the initial attachment to host cells may provide novel targets for drug development and 
potential new vaccine strategies able to effectively interrupt early host-pathogen 
interactions. 
 
There is increasing evidence of the significant importance of two well characterised, 
major adhesins of M.tb on interactions with host cells. Actively multiplying M.tb bacilli 
in the lung tissues upregulated hbhA expression, prior to the cellular immune response 
effectively containing the infected areas (Delogu et al., 2006). HBHA was confirmed 
as a mediator of host-pathogen interactions and an adherence factor, by inhibiting 
HBHA-mediated hemagglutination and attachment of bacilli to epithelial cells using 
monoclonal antibodies against HBHA (Menozzi et al., 1996). Pethe et al. (2001) 
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reported a HBHA-deficient strain to show a reduction in the adhesion to and invasion 
of A549 pulmonary cells by 60% and 80% respectively, relative to the wild-type strain.  
Alteri et al. (2007) confirmed the presence of aggregative, flexible proteins (with 
biochemical, functional and morphological properties mirroring that of known bacterial 
pili) in sera obtained from patients with active tuberculosis, and showed that Rv3312A 
encodes M.tb pili (MTP), a surface protein with adhesive properties. Recent studies 
elucidated a key role for this MTP protein encoded by Rv3312A (mtp) in biofilm 
production (Ramsugit et al., 2013), and as a novel adhesin and invasin of M. 
tuberculosis in its interaction with THP-1 macrophages (Ramsugit and Pillay 2014) and 
pulmonary epithelial cells (Ramsugit et al., 2016). Similarily to HBHA, a mutant strain 
deficient in MTP was significantly reduced in its ability to adhere to and invade A549 
cells relative to the wild type strain V9124 by 69 % and 56 % respectively (Ramsugit 
et al., 2016). Ramsugit et al. (2016) proposed that collectively, the available data on 
both adhesins would suggest that MTP performs marginally better as an adhesin than 
HBHA, whilst the latter may perform a more effective role as an invasin.  
The current study therefore, attempted to provide insight into the role of HBHA and 
MTP in concert, in adhesion to and invasion of A549 pulmonary epithelial cells, using 
a double knockout mutant (ΔDM) strain lacking both the genes. Both adhesins 
demonstrated a significant role in adhesion and invasion. The restoration of gene 
function using complementation of each gene separately, suggests that in the 
F15/LAM4/KZN susceptible strain, MTP may have a greater capacity as an invasin of 
A549 cells than HBHA. However, HBHA and MTP appear to be similar in their role 
as adhesins. This may allude to potential compensatory mechanisms being upregulated 
in the absence of either one of the major adhesins, and adhesion capacity being 
supplemented in the complemented double mutants by expression of additional primary 
and moonlighting adhesin molecules, such as GAPDH (gap), malate synthase (glcB), 
Cpn60.2 (groEL2), Rv3717 (N-acetylmuramoyl-L-alanine amidase), Rv0309 (L,D-
transpeptidase) 19 kDa lipoprotein antigen and DnaK (Govender et al., 2014). 
Collectively, the data suggests that these two proteins independently play major roles 
in the overall adhesion-invasion capacity of M.tb V9124, and in combination, this is 
significantly increased. Therefore, these two surface-associated structures in 
combination present an attractive option as powerful targets for potential vaccine and 
or drug development.  
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A limitation of the study was the absence of a double complement strain to restore full 
gene function to the double mutant strain. The single genes were independently 
complemented in the double mutant in order to establish and understand the individual 
contribution of each gene to the adhesion and invasion capacity of the V9124 strain, 
relative to each other and in comparison, to the double mutant strain. This insight would 
not have been possible if a double complement was used. Future studies involving the 
fully complemented double mutant alongside the single complemented strains to assess 
the combined effect of the loss of these genes in regulation of key compensatory 
pathways need to be explored, in both in vitro and in vivo models. 
 
The development of the double mutant strain additionally pre-empted the generation of 
the single mutant strain ΔhbhA. The availability of both the hbhA and mtp single gene 
deletion mutant strains, as well as the double mutant strain, encourages prospective 
future studies to directly compare the contribution of HBHA and MTP in adhesion and 
invasion assays in macrophage and mouse models, as well as global transcriptomics to 
ascertain host immune responses, and pathogen gene regulation. 
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CHAPTER 5: SYNTHESIS 
 
1. Overview 
 
Studies on the roles of mycobacterial adhesin proteins in pathogenesis and disease 
dissemination have highlighted their importance as potential targets either for 
development of drugs, or vaccines or diagnostic tests (Díaz-Silvestre et al., 2002; 
Kinhikar et al., 2006; Alteri et al., 2007; Ragas et al., 2007; Hickey et al., 2010; Kumar 
et al., 2013; Ramsugit et al., 2013; Naidoo et al., 2014; Esparza et al., 2015; Ramsugit 
et al., 2014; Ramsugit et al., 2016). 
 
 
The current study undertook to establish the importance of the combination of 2 major 
adhesins of Mycobacterium tuberculosis, curli pili (MTP) and the heparin binding 
haemagglutinin adhesin (HBHA), in pathogenesis. These molecules had previously 
been shown independently to be potential biomarkers that may be targeted for 
therapeutic strategies (Naidoo et al., 2014; Maio et al., 2018).  A functional genomics 
approach was used to disrupt the two genes encoding these adhesin proteins, to produce 
incompletely transcribed proteins with impeded functionality.   
 
In order to establish the effect of a lack of functional MTP and HBHA proteins, a double 
mutant gene knockout strain, ΔhbhA-mtp (ΔDM), deficient in functional gene copies of 
both mtp and hbhA, was generated. Additionally, complemented ΔDM strains, each 
restoring expression of a single gene, were constructed. These strains were used 
alongside the double mutant and wildtype strains to elucidate MTP and HBHA function 
in growth and viability, as adherence factors in biofilm formation, as well as in their 
interaction with host epithelial cells. 
 
 
2. Literature and background in support of study feasibility 
 
In Chapter 1, the current body of knowledge was reviewed in detail to provide 
background and insight into the problem at hand, the current status of therapeutics, and 
methods currently being implemented in research endeavours. The historic evolution 
and development of M.tb to become the debilitating global pathogen, as well as the 
mechanisms it uses to engage with, infect and evade the host was described and 
outlined. Overall, a picture was painted that highlighted the staggering nature of the 
122 
 
global epidemic, and the crisis resulting from drug resistance and TB/HIV co-infections 
in population-dense, low income settings. The deficit of effective drug and vaccine 
candidates, as well as the lack of available true POC tests that may be applied in high-
burden settings was explained. Commentary was provided looking at the current 
pipelines in terms of drug candidates, vaccines and POC diagnostics in development, 
showing the ongoing progression toward finding solutions to attack and alleviate the 
problem from every perspective. Further to this, the rationale behind the choice of the 
target molecules in the study was established, with a basic introduction on their 
importance in TB pathogenesis.  
 
Chapter 2 (Govender et al., 2014) presented a more detailed review on the adhesin 
family of molecules. This served to further discuss the role of adhesins in the 
pathogenicity of Mycobacterium tuberculosis, whilst providing insight into structural 
and functional characteristics of both well-established and putative novel adhesins of 
the pathogen. Additionally, thorough rationale and insights were provided in support of 
the potential application of a range of M.tb adhesin molecules as valuable and 
successful targets for the development of TB therapeutics. Key messages include the 
support for the use of the lesser-studied host cell of M.tb, the alveolar pulmonary 
epithelial cell as an experimental model, as well as an explanation of how mycobacterial 
adhesins engage with host cells to perpetuate infection. Another key message, was 
discussion around “moonlighting adhesins” – these include the chaperonin protein 
encoded by cpn60.2, the glyoxylate shunt enzyme malate synthase, the glycolysis 
protein GAPDH, as well as the heparin-binding haemagglutinin adhesin, HBHA. These 
proteins were earmarked to be given serious consideration for further development in 
strategic infection control strategies. 
 
Cumulatively, these initial chapters presented knowledge to allow for a deeper 
understanding of the impact of the pathogen on the world population, and the challenges 
encountered in reducing the infection burden. They offer insights on potential targets 
for therapeutic development, and strong motivating foundation and rationale for the 
research questions that were addressed in the study presented in this thesis. 
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3. Generating mutants:  genetic manipulation of V9124 to construct mutant and 
complemented strains to assess gene function 
 
As a preliminary basis of the study, and in order for the experimental assays to be 
performed, a number of molecular techniques needed to be completed to allow for the 
construction and molecular confirmations of the model organisms. The wildtype, 
control organism, M. tuberculosis V9124 (a drug-susceptible strain belonging to the 
F15/LAM4/KZN family) was subject to genetic manipulation using the technique of 
specialized transduction with phasmids containing allelic exchange substrates to 
construct mutant and complemented strains to assess gene function. 
 
Initially, a single mutant, ΔhbhA, was generated using a phage carrying an allelic 
exchange substrate targeting ~80% of the hbhA gene. Thereafter, a second phage 
carrying a γδ-resolvase gene was used to perform specialized transduction on a PCR 
and Sanger sequencing confirmed ΔhbhA single mutant. The phage served to remove 
the resistance gene portion (hygB-sacB) of the hbhA AES inserted in the native gene 
within the genome that was used to disrupt gene expression. The resolvase acted on the 
γδ-resolvase sites flanking the hygB-sacB cassette to unmark the ΔhbhA single mutant. 
The unmarked ΔhbhA single mutant was confirmed by PCR and Sanger sequencing. 
This was used as a parent strain to generate the ΔhbhA-mtp double mutant strain, as 
described above, using a phage carrying an allelic exchange substrate targeting ~80% 
of the mtp gene. The double mutant strain ΔhbhA-mtp was confirmed by PCR and 
Sanger sequencing, before being used as the parent strain for complementation.  
 
Complementation was performed with individual genes to produce single 
complemented strains, ΔhbhA-mtp-hbha comp and ΔhbhA-mtp-mtp comp. The hbhA-
complementation plasmid pMV261-hbhA was generated by ligating the purified whole 
wildtype hbhA gene into the pMV261 episomal plasmid backbone with a kanamycin 
selective gene. The plasmid was confirmed by restriction digest, PCR and Sanger 
sequencing prior to being electroporated into the ΔhbhA-mtp double mutant strain for 
complementation with hbhA. Positive transformants were screened and confirmed by 
PCR and Sanger sequencing. 
 
Similarily, the pMV261-mtp plasmid (harvested from a confirmed Δmtp single mutant 
by CTAB gDNA extraction followed by plasmid extraction and purification) was 
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electroporated into the ΔhbhA-mtp double mutant strain for complementation with mtp. 
Positive transformants were screened and confirmed by PCR and Sanger sequencing. 
 
These strains were then used to carry out the subsequent downstream experiments 
including growth assays by OD600nm readings and CFU counts, viability assay by means 
of the resazurin microplate assay, biofilm quantification by means of crystal violet 
staining and the adhesion and invasion assay on A549 pulmonary epithelial cells. 
 
 
4. HBHA and MTP facilitate growth, but not viability and biofilm formation 
 
To determine the dual contribution of the HBHA and MTP proteins to the growth, 
viability and biofilm formation in the F15/LAM4/KZN drug-sensitive strain V9124, 
the double mutant strain ΔhbhA-mtp, generated by phage-mediated mycobacterial 
specialized transduction, as described above, was subjected to the growth, viability and 
biofilm assays alongside the two single-gene complemented and wildtype strains. 
 
The growth assays, by means of OD600nm quantification and CFU counts indicated that 
HBHA and MTP in combination have a significant effect on the in vitro growth of M.tb. 
The growth of the independently complemented double mutant strains suggested that 
the contribution of each adhesin was approximately equal. Even though the growth rate 
was significantly impaired, the double mutant strain remained metabolically viable 
relative to the other strains, thus, suggesting that HBHA and MTP do not contribute to 
the metabolic activity of M.tb. 
 
The concurrent removal of hbhA and mtp resulted in a non-significant 8.82% reduction 
(p > 0.05) in biomass in comparison to the wild type V9124. The ΔDM hbhA 
complemented strain (hbhA expression restored) showed a significant reduction in 
biomass, and when compared to the lower, insignificant reduction noted in the ΔDM 
mtp complemented strain (mtp expression restored). This suggests that MTP may have 
a greater effect on biofilm formation than HBHA, a finding supported by Ramsugit et 
al. (2013). 
 
In generating the double mutant and complemented strains, the study was able to 
illustrate a potential compounded effect on bacterial phenotype, including growth, 
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viability and biofilm formation. This work supports the postulate that the two major 
M.tb adhesins promote in vitro growth and biomass formation in the F15/LAM4/KZN 
susceptible strain, and thus contribute to the pathogenicity of this strain. These results 
suggest the importance of the two adhesins and their potential value when targeted in 
combination for the development of therapeutic interventions. 
 
 
5. A loss of hbha and mtp gene expression collectively reduces adhesion and 
invasion capacity of M. tuberculosis 
 
The combined effect of HBHA and MTP in the adhesion to and invasion of host cells, 
was established in an in vitro tissue culture infection model with A549 pulmonary 
epithelial cells. Significant reduction was shown in adherence to (81%) and invasion of 
(83%) A549 pulmonary epithelial cells by ΔhbhA-mtp double mutant strain (ΔDM), 
relative to V9124 (p = 0.00). Complementation with hbhA partially restored adhesion 
and invasion to 45% and 29% respectively, while complementation with mtp partially 
restored adhesion and invasion to 43% and 40% respectively, relative to the V9124 
wildtype.  
 
Collectively, the data suggests that these two proteins independently play major roles 
in the overall adhesion-invasion capacity, with MTP having a potentially greater 
invasin role than HBHA in the M.tb F15/LAM4/KZN susceptible strain V9124. 
However, in combination, invasion capacity is significantly increased. HBHA and MTP 
appear to be similar in their role as adhesins. Therefore, these two surface-associated 
structures in combination play a significant role in the overall adhesion-invasion 
capacity of M.tb, and present an exciting option as powerful combined targets for 
therapeutic drug and vaccine development. 
 
6. General Discussion 
 
Anti-adhesion therapies, although conceptually appealing, remain under-developed and 
un-utilized in the treatment of bacterial infections, with little to no targeted blocking 
antibodies currently being investigated for vaccine development. This hesitance is 
predominantly due to the expression of multiple adhesion molecules occurring in a 
well-modulated tissue- and time-specific manner from initial contact throughout the 
course of an infection (Stones and Krachler, 2015). Despite relatively small genomes, 
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mycobacteria possess a host of molecules that have suspected moonlighting function as 
adhesins outside of their core functions.  These are able to circumvent the effects of a 
loss of expression of key genes by initiating cascades of compensatory mechanisms, 
using these moonlighting molecules as back-up adhesins (Neyrolles et al., 2001; 
Kinhikar et al., 2006; Kumar et al, 2013; Govender et al., 2014). It is most likely that 
M.tb possesses unidentified genes encoding novel factors that hold roles in host cell 
adherence. Indeed, a major portion of the Mycobacterial genome encodes hypothetical 
proteins that have yet to be studied and functionally characterized (Mazandu & Mulder, 
2012; Kumar et al, 2013; Mann et al., 2016). This challenging issue of redundancy and 
functional duplication, a potential confounding factor in gene knockout studies, is 
further highlighted by the presence of the large number of predicted adhesins (as 
reviewed by Govender et al., 2014).  
 
The approach applied in this study highlights the usefulness of targeting multiple 
adhesin or moonlighting proteins as a way to effectively mitigate this pitfall in adhesin-
directed vaccine development, as the study outcomes may allude to potential 
compensatory mechanisms being up-regulated in the absence of either one of the major 
adhesins, and adhesion capacity being supplemented in the complemented double 
mutants by expression of additional primary and moonlighting adhesin molecules. 
 
A limitation of this study design was the independent complementation of the double 
mutant strain by the individual genes in separate episomal expression plasmids to 
generate hypothetical “single mutant strains”. This resulted in partial complementation 
of either hbhA or mtp in the ΔDM to fully restore only single gene function, and the 
absence of a truly double complement strain to restore full gene function to the double 
mutant.  
 
The motivation for generating this type of individual single complemented ΔDM strains 
was to attempt to assess and establish the individual contribution of each adhesion 
molecule in the assays performed. In doing this, it was hoped that differences could be 
detected to allow us to establish if one gene had variable or increased effects on growth, 
viability and biofilm formation over the other. In this way, a greater understanding of 
the individual contribution of each gene to the adhesion and invasion capacity of the 
V9124 strain, relative to each other, and (in comparison) to the double mutant strain, 
127 
 
could be gathered. This insight would not have been possible if a double complement 
was used. 
 
7. Conclusions 
 
The findings of the present study illustrate the limited effects of a lack of both these 
genes on bacterial phenotypes, including viability and biofilm formation, while a 
significant compounded effect is recognized in terms of attenuated growth capacity. 
Interestingly, MTP appears to have a greater impact as an invasin of A549 pulmonary 
epithelial cells than HBHA, while both HBHA and MTP appear to be similar in their 
role as adhesins in this cell type.  
 
These outcomes support the postulate that the two major M.tb adhesins promote in vitro 
growth (and biomass formation less significantly) in the F15/LAM4/KZN susceptible 
strain, while playing key roles in the adhesion and invasion capacity of M.tb, thus 
contributing to the overall pathogenicity of the organism. These two surface-associated 
molecules, in combination, present an appealing option as powerful targets for potential 
vaccine and or drug development. This study would then hopefully serve to indicate the 
value of investigating reducing the functionality of both the major adhesin proteins by 
potential targeted blocking antibodies, in order to prevent bacterial entry into the host 
cells, thereby working toward reducing bacterial proliferation and evasion. 
  
8. Future work 
 
To gain a comprehensive and detailed understanding of the combined effect of these 
two key adhesin-expressing genes acting in concert, further studies utilizing a double-
complemented hbhA-mtp mutant strain are needed as supplementary steps to 
substantiate and truly validate the outcomes of this study. Such a complemented strain 
would enable the full restoration of gene function when both genes are complemented. 
 
Further studies looking into the impact of the absence of these genes on signaling 
pathways and gene regulation networks (both in M.tb and the host) would shed more 
light into the role they play in facilitating bacterial proliferation, and the potential effect 
that they may have on host immune modulation.  
 
128 
 
Studies utilizing the fully complemented double mutant alongside the single 
complements to assess the combined effect of the loss of these genes in regulation of 
key compensatory pathways need to be explored, both in vitro and in vivo. They may 
also serve to indicate and highlight roles of other potential compensatory genes to be 
considered as novel therapeutic targets for development alongside hbhA and mtp. The 
activity of these supplemental genes with moonlighting ability may come to the surface 
and indicate if they may be directly impacted by gene expression or repression of either 
hbhA or mtp. 
 
The development of the double mutant strain additionally necessitated and pre-empted 
the generation of the single mutant strain, ΔhbhA. The availability of both the hbhA and 
mtp single gene deletion mutant strains, encourages prospective future studies 
alongside the double mutant strain to directly compare the contribution of HBHA and 
MTP in adhesion and invasion assays in macrophage and mouse models, as well as 
transcriptomic-based investigations to ascertain host immune responses, and pathogen 
gene regulation processes.  
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APPENDICES 
 
Appendix 1 – Supplementary images: 
 
 
Fig. 1: Biofilm assay - no visible difference in biofilm formation is noted between the 
wildtype, double mutant and complemented strains, after a 5 week incubation, with 
blank culture media as a negative control. 
 
 
 
Fig. 2: Growth and viability assay data highlighting the hbhA single mutant and 
complemented hbhA single mutant strain, relative to V9124 and ΔDM. 
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Appendix 2 - Supplementary tables: 
 
Chapter 3 – Paper 2 
 
 Table 1: Growth Assay – Mean Optical Density (600nm)* 
Timepoint V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Day 0 0,01 0,02 0,03 0,01 
Day 3 0,04 0,03 0,00 0,01 
Day 6 0,29 0,21 0,16 0,13 
Day 9 0,61 0,34 0,45 0,43 
Day 12 0,76 0,44 0,64 0,60 
Day 15 1,02 0,59 0,80 0,81 
Day 18 1,20 0,76 0,91 0,92 
Day 21 1,88 0,95 1,11 1,11 
 
 
Table 2: Growth Assay – Mean Colony forming units per mL (CFU/mL)* 
Timepoint V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Day 0 1,33E+06 5,00E+05 5,00E+05 5,00E+05 
Day 3 2,33E+07 1,17E+07 1,83E+07 2,50E+07 
Day 6 1,43E+08 9,83E+07 7,67E+07 4,67E+07 
Day 9 7,83E+08 3,17E+08 3,50E+08 3,17E+08 
Day 12 9,00E+08 4,50E+08 5,67E+08 5,50E+08 
Day 15 1,23E+09 5,83E+08 6,83E+08 6,50E+08 
Day 18 1,38E+09 8,67E+08 9,17E+08 8,67E+08 
Day 21 1,43E+09 9,17E+08 1,15E+09 1,12E+09 
 
 
Table 3: Resazurin Microplate Viability Assay – Mean Absorbance (600nm)* 
Timepoint V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Day 0 9,55E-02 1,90E-01 2,02E-01 1,24E-01 
Day 3 8,43E-01 6,14E-01 5,25E-01 4,77E-01 
Day 6 1,37E+00 1,15E+00 1,48E+00 1,56E+00 
Day 9 7,96E-01 1,04E+00 1,04E+00 8,33E-01 
Day 12 1,24E+00 1,19E+00 1,24E+00 1,32E+00 
Day 15 9,97E-01 1,16E+00 9,91E-01 9,93E-01 
Day 18 1,04E+00 1,11E+00 1,13E+00 1,03E+00 
Day 21 2,05E+00 2,25E+00 2,17E+00 2,21E+00 
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Table 4: Biofilm Assay – Absorbance 600nm* 
 V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Mean Run 1 0,61 0,53 0,55 0,56 
Mean Run 2 0,55 0,53 0,49 0,53 
Mean Run 3 0,58 0,53 0,52 0,54 
Mean 0,58 0,53 0,52 0,54 
Std. Dev 0,02 0,00 0,02 0,01 
Relative % 100,00 91,18 90,70 94,40 
      
 
*Note: Data presented are overall means of three biological repeats within three technical 
repeats 
 
 
 
Chapter 4 – Paper 3 
 
Table 5: Adhesion Assay – % Adhesion 
 V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Mean Run 1 0,25 0,05 0,12 0,11 
Mean Run 2 0,27 0,05 0,12 0,10 
Mean Run 3 0,21 0,04 0,09 0,10 
Mean 0,24 0,05 0,11 0,10 
Std. Dev 0,0193 0,0035 0,0110 0,0014 
      
 
 
Table 6: Adhesion Assay – % Relative Adhesion 
 V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Mean Run 1 100,00 19,35 48,00 44,00 
Mean Run 2 100,00 18,52 44,44 37,04 
Mean Run 3 100,00 19,05 42,86 47,62 
Mean 100,00 18,97 45,10 42,89 
Std. Dev 0 0 2 3 
      
 
 
Table 7: Invasion Assay – % Invasion 
 V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Mean Run 1 0,25 0,04 0,07 0,10 
Mean Run 2 0,27 0,04 0,07 0,10 
Mean Run 3 0,21 0,04 0,07 0,09 
Mean 0,24 0,04 0,07 0,09 
Std. Dev 0,0153 0,0011 0,0013 0,0021 
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Table 8: Invasion Assay – % Relative Invasion 
 V9124 ΔDM ΔDM-hbhA comp ΔDM-mtp comp 
Mean Run 1 100 16,00 28,00 40,00 
Mean Run 2 100 15 26 37 
Mean Run 3 100 19 33 43 
Mean 100 17 29 40 
Std. Dev 0 1 2 2 
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Appendix 3 – Biomedical Research Ethics Committee (BREC) Approval 
Letters – Full Study Approval & Recertification: 
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